(19)
(11)EP 2 591 776 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
21.10.2015 Bulletin 2015/43

(21)Application number: 11774262.7

(22)Date of filing:  21.03.2011
(51)International Patent Classification (IPC): 
A61K 31/165(2006.01)
A61P 31/00(2006.01)
A61P 43/00(2006.01)
A61P 31/04(2006.01)
A61P 29/00(2006.01)
A61P 37/00(2006.01)
A61K 36/815(2006.01)
(86)International application number:
PCT/CN2011/000478
(87)International publication number:
WO 2011/134271 (03.11.2011 Gazette  2011/44)

(54)

USE OF KUKOAMINE A AND KUKOAMINE B

VERWENDUNG VON KUKOAMIN A UND KUKOAMIN B

UTILISATION DE KUKOAMINE A ET DE KUKOAMINE B


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 27.04.2010 CN 201010156503

(43)Date of publication of application:
15.05.2013 Bulletin 2013/20

(73)Proprietors:
  • The First Affiliated Hospital, Third Military Medical Universty, PLA
    Chongqing 400038 (CN)
  • Tianjin Chasesun Pharmaceutical Co., Ltd
    Tianjin 301700 (CN)

(72)Inventors:
  • ZHENG, Jiang
    Shapingba District Chongqing 400038 (CN)
  • LIU, Xin
    Shapingba District Chongqing 400038 (CN)
  • ZHENG, Xinchuan
    Shapingba District Chongqing 400038 (CN)
  • ZHOU, Hong
    Shapingba District Chongqing 400038 (CN)
  • CAO, Hongwei
    Shapingba District Chongqing 400038 (CN)
  • WANG, Ning
    Shapingba District Chongqing 400038 (CN)
  • LU, Yongling
    Shapingba District Chongqing 400038 (CN)

(74)Representative: Wichmann, Hendrik et al
Wuesthoff & Wuesthoff Patentanwälte PartG mbB Schweigerstraße 2
81541 München
81541 München (DE)


(56)References cited: : 
CN-A- 101 829 075
  
  • LEE K H ET AL: "Xia-Bai-San inhibits lipopolysaccharide-induced activation of intercellular adhesion molecule-1 and nuclear factor-kappa B in human lung cells", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 124, no. 3, 30 July 2009 (2009-07-30) , pages 530-538, XP026349887, ISSN: 0378-8741 [retrieved on 2009-05-18]
  • LIU XIN ET AL.: 'Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment.' BRITISH JOURNAL OF PHARMACOLOGY., [Online] vol. 162, no. 6, 22 February 2011, ISSN 1476-5381 pages 1274 - 1290 ISSN: 1476-5381 Retrieved from the Internet: <URL:http.//onlinelibrarv.wiley.com/doi/10. 1111/j.1476-5381.2010.01114.x /pdf>
  • LIU XIN ET AL.: 'Dual targets guided screening and isolation of Kukoamine B as a novel natural anti-sepsis agent from traditional Chinese herb Cortex lycii.' INTERNATIONAL IMMUNO-PHARMACOLOGY. vol. 11, no. 1, 10 November 2010, ISSN 1567-5769 pages 110 - 120
  • ZHOU JIE ET AL.: 'Research progress on chemical constituents and pharmacological effect of Chinese Wolfberry Root-bark.' SHANXI JOURNAL OF TRADITIONAL CHINESE MEDICINE vol. 24, no. 2, February 2008, CHINESE, pages 47 - 48
  • FU JIANFENG ET AL.: 'Experimental study of the anti-endotoxin activity ofCL-5 extracted from cortex lycii.' JOURNAL OF TRAUMATIC SURGERY vol. 10, no. 3, 2008, CHINESE, pages 260 - 263
  • HADJIPAVLOU-LITINA DIMITRA ET AL: "Kukoamine A analogs with lipoxygenase inhibitory activity.", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY OCT 2009, vol. 24, no. 5, October 2009 (2009-10), pages 1188-1193, XP008172270, ISSN: 1475-6374
  • Gajanan Sherbet: "Bacterial infections and the pathogenesis of autoimmune conditions", British Journal of Medical Practitioners, 1 March 2009 (2009-03-01), page 6, XP055182491, Retrieved from the Internet: URL:http://www.bjmp.org/files/march2009/bj mp0309sherbet.pdf
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

FIELD



[0001] The present invention relates to use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease caused by bacteria.

[0002] Sepsis and autoimmune disease are caused by body's excessive immune response, to which there were no reliable and effective drug strategies yet. Sepsis is an acute systemic inflammatory response syndrome, the mortality rate of which could be as high as 30%-70%, and it has been a serious threat to critically ill patients. According to incomplete statistics, over 3, 000, 000 people are diagnosed with sepsis every year in China, and more than half a million people died from it. Autoimmune disease is a chronic inflammation disease. As shown by epidemiological data, the incidence rate of autoimmune disease is about 3.2%-5.3% in China, and it has been one of the leading causes of death of women under 65. Therefore, appropriate prevention and treatment measures for sepsis and autoimmune disease have been a hot spot for clinical research.

[0003] At present, the treatment of sepsis and autoimmune disease is still very difficult, and empiric non-specific anti-inflammatory agents, such as glucocorticoids, are still the mainstay of treatment. However, these drugs not only rarely improve survival rates or survival quality of patients, but also may cause serious adverse reaction. In the past decades, the research of prevention and treatment of sepsis and autoimmune disease has been focused on inhibition of key molecules in immune response and correcting disorder of blood coagulation, complement, and etc. which are immediate cause of organ injury. Results of related studies show that it is not only difficult for these measures to achieve curative effect (immune response in vivo is a complicated network system which is diffcult to regulate), these measures may also aggravate the disorder of immune system and cause further deterioration of pathogenetic condition. Accordingly, related studies have not got any breakthrough so far, and there are no reliable and effective new drugs entering clinical trails. All these facts indicate that we need to understand the nature of pathogenesis and trigger of sepsis and autoimmune disease, and look for specific curative drugs.

[0004] In recent years, impressive progress has been made in pathogenesis of sepsis and autoimmune disease. At present in addition to influence of endocrine, genetic and environmental factors, bacterial endotoxin/ lipopolysaccharide (LPS) and unmethylated DNA (CpG DNA) of bacteria are considered as trigger factors which start an attack of sepsis and autoimmune disease. Many studies have confirmed that LPS and CpG DNA could induce sepsis together or separately, and they could also induce or aggravate symptoms of rheumatoid arthritis. In the course of acute infection, rapid invasion of pathogens may generate large amount of LPS and CpG DNA, which induce large number of expression and release of various inflammatory mediators, such as TNF-α, IL-1β, IL-6 etc., within a short priod of time, leading to early organ dysfunction and late immune paralysis, and resulting in death of sepsis patients. For autoimmune disease, the persistence of LPS and CpG DNA may lead to persistance and chronic evolution of inflammatory reaction, and induce mass production of inflammatory mediators, immunoglobulins and rheumatoid factor etc., which form immune complex depositing on synovium, activate complement, product anaphylatoxin, resulting in inflammatory pathologic damage, and eventually leading to organ injury. Thus it can be seen that effective antagonism on LPS and CpG DNA could prevent and cure sepsis and autoimmune disease from the source. Related drug researches have confirmed that the blockade of irritant reaction of LPS and CpG DNA to immunocyte and the inhibition of release of inflammatory mediators, like TNF-α, have obvious therapeutic effects on sepsis and autoimmune disease. Therefore, antagonistic activity on LPS and CpG DNA could reflect preventive and therapeutic effects of certain drugs to sepsis and autoimmune disease.

[0005] Traditional Chinese herbs for clearing away the heat-evil and expelling superficial evils have long been used in immune system disorder, such as sepsis and autoimmune disease, and have a good curative effect in the clinical practice. Modern pharmacological studies have shown that there are certain compositions existed in traditional Chinese herbs, which could bind and antagonize the pathogen-associated molecular patterns, e.g. LPS and CpG DNA, and serve as important material basis in correcting immunologic derangement, preventing and curing sepsis and autoimmune disease. Da Chengqi decoction, Reduqing, Reduping and other agents can reduce levels of LPS, TNF-α, IL-1 and IL-6 in circulating blood of sepsis patients; Lonicera japonica. Thunb., Forsythia suspensa (Thunb.) Vahl, Scutellaria baicalensis Georgi, Artemisia annua L. and other more than 20 kinds of Chinese herbal medicines have good antagonistic activity on pathogen-associated molecular patterns, e. g LPS, in vitro experiments; decoction of Atractylodis macrocephalae rhizome can significantly reduce the elevated levels of LPS and TNF-α in serum of patients with rheumatoid arthritis, suppress the levels of IgG, IgA and IgM in serum, reduce RF (rheumatoid factor) positive rate, and thus achieve treatment of rheumatoid arthritis; Langchuang formula, which consists of 7 kinds of Chinese herbal medicines for heat-clearing and detoxicating, such as Oldetilandia diffusa (Willd.) Roxb., Scutellaria barbata D. Don, Arnebia enchroma (Royle) Johnst., Salvia miltiorrhiza Bge., Leonurus japonicus Houtt. etc., can inhibit the activation of T cell and B cell, reduce the generation of IL-6,IL-10 and autoantibody, and play a role in the treatment of systemic lupus erythematosus. However, the complicated constituents and uncertainty of drug safety, to a significant degree, limit the use of traditional Chinese herbs in clinical treatment. Therefore, separation of monomer, which can antagonize LPS and CpG DNA, is of great significance in prevention and treatment of sepsis and autoimmune disease.

[0006] Lycii cortex is the dried root bark of Lycium chinense Mill. or Lycium barbarum L of the Solanaceae family. In traditional Chinese medicine theory, it has the effects of clearing away the heat-evil and expelling superficial evils. Modern pharmacological studies have found that Lycii vortex contains alkaloids, organic acids, anthraquinones and peptides, and it plays a pharmacological role of anti-hypertension, anti-hyperglycemia, relieving fever and analgesia. However, researches and applications on Lycii cortex antagonizing LPS and CpG DNA and treating sepsis and autoimmune disease have not been reported in domestic and foreign literatures and domestic invention patents up to now. Gajanan Sherbet, British Journal of Medical Practitioners, 2009:2(1), p. 6-13 reviews bacterial infections as cause for autoimmune diseases via upregulation of toll-like receptors (TLR) and nitric oxide synthase (NOS). Lee et al. Journal of Ethnopharmacology 124(3): 530-538 (2009) discloses a Chinese medicine comprising an extract of 4 raw herbs including cortex lyci, which extract was shown to inhibit inflammation in lung tissue in response to LPS.

[0007] Hadjipavlou-Litina Dimitra et al. Journal of Enzyme Inhibition and Medicinal Chemistry 24(5): 1188-1193 (2009) discloses Kukoamine A and B, and therapeutic uses thereof.

SUMMARY OF THE INVENTION



[0008] The purpose of present invention is to overcome the major defect of uncertainty of material basis and mechanisms of constituents and extractives in traditional Chinese medicine, develop a safe, effective, quality controllable drug for prevention and treatment of sepsis and autoimmune disease, and solve the lack of effective drugs in clinical treatment at present. The technical solution of present invention is:

The invention relates to the use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of bacterial sepsis and autoimmune disease caused by bacteria.



[0009] Said Kukoamine A and Kukoamine B are extracted from Lycii cortex in traditional Chinese medicine.

[0010] Said drug is used for antagonizing the key factors, i.e. bacterial endotoxin/ lipopolysaccharide (LPS) and unmethylated DNA of bacteria, which induce the development of sepsis and autoimmune disease caused by bacteria.

[0011] Said Lycii cortex is the dried root bark of Lycium chinense Mill. or Lycium barbarum L. of the Solanaceae family.

[0012] The applicant persists for a long time in drug research of antagonizing pathogen-associated molecular patterns targeting at LPS and CpG DNA. Through biosensor screening and tracking platform established, the applicant screens and directionally isolates the activated monomer, which has effects of binding and antagonizing LPS and CpG DNA, from traditional Chinese medicine for clearing away the heat-evil and expelling superficial evils.

[0013] The present invention uses Lycii vortex as raw material, establishes drug screening and directional separating platform targeting at lipid A and CpG DNA, and uses binding activity of Chinese herb extracts with lipid A and CpG DNA as screening indicators. Raw material was boiled with water; then, it was extracted, isolated and purified respectively with methods of macroporous adsorptive resins, cation exchange and reversed-phase high-performance liquid chromatography; through pharmacological evaluation in vivo and in vitro, such as experiments of neutralization of LPS in vitro, experiments of inhibition on bindings of LPS and CpG DNA with cells, experiments of inhibition on inflammatory reaction caused by stimulations of LPS and CpG DNA, and experiments of protection of model animal with sepsis, eventually, two active constituents, Kukoamine A (KA) and Kukoamine B (KB), which have good antagonistic effect on LPS and CpG DNA, were screened out.

[0014] By means of activity tracking, the present invention separates active constituents antagonizing LPS and CpG DNA from traditional Chinese herbs, and provides safe, reliable and effective drugs for prevention and treatment of sepsis and autoimmune disease.

[0015] Said Kukoamine A and Kukoamine B are spermine-like alkaloids extracted from Lycii cortex. They are a pair of isomeride, with the same molecular formula of C28H42N4O6 and molecular weight of 530.66. Their chemical structures are respectively as follows:





[0016] kukoamine A and Kukoamine B for use of the present invention have a brilliant prospect of being effective drugs in treatment of sepsis and autoimmune disease. Specifically experiments in vitro demonstrated that Kukoamine A and Kukoamine B have high affinity with LPS and CpG DNA, can significantly neutralize LPS and CpG DNA, blockade their bindings with RAW264.7 cells (murine macrophages), inhibit the expression and release of inflammatory mediators (TNF-α, IL-6, etc.) in RAW264.7 cells induced by LPS and CpG DNA, and finally blockade the inflammatory activation of cells and prevent disorders of the immune response. It has been observed in vivo experiments that Kukoamine A and Kukoamine B can lower the levels of LPS and TNF-α in mice injected with heat-killed Escherichia coli (mimic vivo injection of LPS and CpG DNA), play a role in antagonism on LPS and CpG DNA, and improve survival rates of the mice.

DESCRIPTON OF THE DRAWINGS



[0017] 

Figure 1 shows the response curve of immobilization of lipid A and CpG DNA, and the binding curve of 6 kinds of traditional Chinese medicine decoction with lipid A and CpG DNA. Wherein Figure 1 a is a response curve of immobilization of lipid A; Figure 1b is a response curve of immobilization of CpG DNA; Figure 1c shows binding reaction of lipid A with Lycii cortex and other 6 kinds of traditional Chinese medicine; Figure 1d shows binding reaction of CpG DNA with Lycii cortex and other 6 kinds of traditional Chinese medicine. The reference number in Figure 1c and Figure 1d separately denotes: 1. Lycii cortex; 2. Paeonia suffruticosa Andr; 3. Cornus officinalis Sieb. et Zucc.; 4. Rheum palmatum L.; 5. Scutellaria. baicalensis Georgi; 6. Cinnamomum cassia Presl;

1. Figure 2 shows constituents separation of CL-1∼5 and their binding reactions with lipid A and CpG DNA. Wherein Figure 2a is the chromatogram of constituents separation of C-1∼5; Figure 2b shows binding reaction of C-1∼5 constituents with lipid A; Figure 2c shows binding reaction of CL-1∼5 constituents with CpG DNA;

Figure 3 shows constituents separation of CL-4a, -4b and -4c and their binding reactions with lipid A and CpG DNA. Wherein Figure 3a is chromatogram of constituents separation of CL-4a, -4b and -4c; Figure 3b shows binding reaction of CL-4 constituents with lipid A; Figure 3c shows binding reaction of CL-4 constituents with CpG DNA;

Figure 4 shows the neutralization of CL-4b constituents with LPS in vitro, and the symbol ** in Figure 4 means p<0.01 vs LPS;

Figure 5 shows the inhibition of CL-4b constituents on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA (CpG). Wherein Figure 5a shows the inhibition of CL-4b constituents on the release of TNF-α and IL-6 in RAW264.7 cells induced by LPS, and Figure 5b shows the inhibition of CL-4b constituents on the release of TNF-α and IL-6 in RAW264.7 cells induced by CpG DNA (CPG); In Figure 5, the symbol * means p<0.05, and ** means p<0.01 vs LPS or CpG DNA (CpG);

Figure 6 shows the protection of CL-4b constituents on mice challenged by lethal dose of heat-killed Escherichia coli (EC) and the symbol * in Figure 6 means p<0.05 vs E.coli. (EC);

Figure 7 shows diagrams of high efficiency liquid chromatography (HPLC) analysis of CL-4b constituents. Wherein Figure 7a is a HPLC diagram of CL-4b1 constituents, Figure 7b is a HPLC diagram of CL-4b2 constituents;

Figure 8 shows binding curves of KA and KB with lipid A and CpG DNA in vitro. Wherein Figure 8a shows the affinity detection of KA and KB with lipid A, and Figure 8b shows the affinity detection of KA and KB with CpG DNA;

Figure 9 shows the neutralization of KA and KB with LPS in vitro. The symbol * in Figure 9 means p<0.05, and ** means p<0.01 vs LPS;

Figure 10 shows the inhibition of KA and KB on the binding of fluorescently-labeled LPS and CpG DNA (CpG) with RAW264.7 cells. Wherein Figure 10a shows the inhibition of KA and KB on the binding of fluorescently-labeled LPS with RAW264.7 cells, and Figure 10b shows the inhibition of KA and KB on the binding of fluorescently-labeled CpG DNA (CpG) with RAW264.7 cells, and the symbol ** in Figure 10 means p<0.01 vs FITC-LPS or 5-FAM-CpG DNA;

Figure 11 shows the inhibition of KA and KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA (CpG). Wherein Figure 11 a shows the inhibition of KA and KB on the release of TNF-α in RAW264.7 cells induced by LPS, and Figure 11b shows the inhibition of KA and KB on the release of TNF-α in RAW264.7 cells induced by CpG DNA. In Figure 11, the symbol * means p<0.05, and ** means p<0.01 vs LPS or CpG DNA;

Figure 12 shows the influence of KA and KB on RAW264.7 cells vitality;

Figure 13 shows the influence of KA and KB on LPS and TNF-α levels in blood of mice challenged by heat-killed Escherichia coli (E.coil.) ATCC 35218. Wherein Figure 13a shows the influence of KA and KB on LPS level in blood of mice challenged by E. coli, and Figure 13b shows the influence of KA and KB on TNF-α level in blood of mice challenged by E. coli. In Figure 13, the symbol * means p<0.05, and ** means p<0.01 vs E.coli. ;

Figure 14 shows binding reactions of KB and PMB with LPS and CpG DNA. Wherein Figure 14a shows the affinity detection of KB and PMB with LPS, and Figure 14b shows the affinity detection of KB and PMB with CpG DNA;

Figure 15 shows the neutralization of KB and PMB with LPS in vitro;

Figure 16 shows the inhibition of KB on the release of TNF-α and IL-6 in RAW264.7 cells induced by LPS and CpG DNA (CPG). Wherein Figure 16a shows the inhibition of KB on the release of TNF-α in RAW264.7 cells stimulated by LPS and CpG DNA (CPG), and Figure 16b shows the inhibition of KB on the release of IL-6 in RAW264.7 cells stimulated by LPS and CpG DNA (CPG). In Figure 16, the symbol ** means p<0.01 vs LPS, and ## means p<0.01 vs CpG DNA;

Figure 17 shows the inhibition of KB and PMB on the release of TNF-α and IL-6 in RAW264.7 cells induced by LPS and CpG DNA (CPG). Wherein Figure 17a shows the inhibition of KB and PMB on the release of TNF-α in RAW264.7 cells stimulated by LPS; Figure 17b shows the inhibition of KB and PMB on the release of TNF-α in RAW264.7 cells stimulated by CpG DNA (CPG); Figure 17c shows the inhibition of KB and PMB on the release of IL-6 in RAW264.7 cells stimulated by LPS; Figure 17d shows the inhibition of KB and PMB on the release of IL-6 in RAW264.7 cells stimulated by CpG DNA (CPG). In figure 17, the symbol * means p<0.05, and ** means p<0.01 vs LPS or CpG DNA;

Figure 18 shows the inhibition of KB and PMB on the release of TNF-α and IL-6 in murine peritoneal macrophages induced by LPS and CpG DNA (CPG). Wherein Figure 18a shows the inhibition of KB and PMB on the release of TNF-α in murine peritoneal macrophages stimulated by LPS; Figure 18b shows the inhibition of KB and PMB on the release of TNF-α in murine peritoneal macrophages stimulated by CpG DNA (CPG); Figure 18c shows the inhibition of KB and PMB on the release of IL-6 in murine peritoneal macrophages stimulated by LPS; and Figure 18d shows the inhibition of KB and PMB on the release of IL-6 in murine peritoneal macrophages stimulated by CpG DNA (CPG). In Figure 18, the symbol * means p<0.05, and ** means p<0.01 vs LPS or CpG DNA;

Figure 19 shows the influence of KB on the mRNA expressions of TNF-α, IL-6, iNOS and COX-2 in RAW264.7 cells stimulated by LPS and CpG DNA (CPG). Wherein Figure 19a shows the inhibition of KB on the mRNA expression of TNF-α in RAW264.7 cells stimulated by LPS and CpG DNA (CPG); Figure 19b shows the inhibition of KB on the mRNA expression of IL-6 in RAW264.7 cells stimulated by LPS and CpG DNA (CPG); Figure 19c shows the inhibition of KB on the mRNA expression of iNOS in RAW264.7 cells stimulated by LPS and CpG DNA (CPG); and Figure 19d shows the inhibition of KB on the mRNA expression of COX-2 in RAW264.7 cells stimulated by LPS and CpG DNA (CPG). In Figure 19, the symbol * means p<0.05, and ** means p<0.01 vs LPS or CpG DNA;

Figure 20 shows the influence of KB on the mRNA expression of TNF-α and IL-6 in murine peritoneal macrophages stimulated by LPS and CpG DNA (CPG). Wherein Figure 20a shows the inhibition of KB on the mRNA expression of TNF-α in murine peritoneal macrophages stimulated by LPS and CpG DNA (CPG), and Figure 20b shows the inhibition of KB on the mRNA expression of IL-6 in murine peritoneal macrophages stimulated by LPS and CpG DNA (CPG). In Figure 20, the symbol * means p<0.05, and ** means p<0.01 vs LPS or CpG DNA;

Figure 21 shows time and dose dependent effects of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA (CPG). Wherein Figure 21 a shows the dose-dependent effects of KB antagonism on LPS and CpG DNA (CPG); Figure 21b shows the time-dependent effects of inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS; and Figure 21 c shows the time-dependent effects of inhibition of KB on TNF-α release in RAW264.7 cells induced by CpG DNA (CPG). In Figure 21, the symbol * means p<0.05, and ** means p<0.01 vs LPS or CpG DNA;

Figure 22 shows the influence of different loading patterns on inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA (CPG). Wherein Figure 22a shows the inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA (CPG), in which KB was loaded after preincubation with LPS or CpG DNA (CPG); Figure 22b shows the inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA (CPG), in which KB was loaded at various time points; Figure 22c shows the inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA (CPG), in which KB was loaded under serum-free conditions. In Figure 22, the symbol * means p<0.05 and ** means p<0.01 vs LPS or CpG DNA;

Figure 23 shows the inhibition of KB on release of TNF-α and IL-6 in RAW264.7 cells induced by various pathogen-associated molecular patterns (LPS, CpG DNA, Pam3CSK4, Poly I:C, TNF-α and IL-1β). WhereinFigure 23a shows the inhibition of KB on TNF-α release in RAW264.7 cells induced by various pathogen-associated molecular patterns, and Figure 23b shows the inhibition of KB on IL-6 release in RAW264.7 cells induced by various pathogen-associated molecular patterns;

Figure 24 shows the detection of KB influence on the binding of LPS and CpG DNA (CPG) with RAW264.7 cells using flow cytometry. Wherein Figure 24a shows the influence of KB on mean fluorescence intensity of LPS on RAW264.7 cell surface, and Figure 24b shows the influence of KB on mean fluorescence intensity of CpG DNA (CPG) on RAW264.7 cell surface. In Figure 24, the symbol * means p<0.05, and ** means p<0.01 vs FITC-LPS or 5-FAM-CpG DNA;

Figure 25 shows the observation of KB influences on binding and cellular internalization of LPS and CpG DNA (CPG) to RAW264.7 cells under a confocal microscopy. Wherein Figure 25a shows the KB influence on binding and cellular internalization of LPS to RAW264.7 cells, and Figure 25b shows the KB influence on mean fluorescence intensity of 5-FAM-CpG DNA on RAW264.7 cell surface. In Figure 25, the symbol * means p<0.05, and ** means p<0.01 vs FITC-LPS or 5-FAM-CpG DNA;

Figure 26 shows the inhibition of KB on the up-regulated expression of TLR4 and TLR9 induced by LPS and CpG DNA (CPG). Wherein Figure 26a shows the inhibition of KB on the up-regulated expression of TLR4 mRNA induced by LPS and CpG DNA (CPG), and Figure 26b shows the inhibition of KB on the up-regulated expression of TLR9 mRNA induced by LPS and CpG DNA (CPG). The symbol ** in Figure 26 means p<0.01 vs LPS or CpG DNA;

Figure 27 shows the inhibition of KB on up-regulated phosphorylation of signaling molecules IκB-α and p38 in RAW264.7 cells stimulated by LPS, CpG DNA (CPG), TNF-α and IL-1β. Wherein Figure 27a shows the degradation of IκB-α in RAW264.7 cells after stimulated by LPS, CpG DNA (CPG), TNF-α and IL-1β for different time (15, 30, 45, and 60 mins), and Figure 27b shows the inhibition of KB on up-regulated phosphorylation of signaling molecules p38 induced by LPS, CpG DNA (CPG), TNF-α and IL-1β, and the inhibition of KB on degradation and phosphorylation of IκB-α, in RAW264.7 cells.

Figure 28 shows the inhibition of KB on NF-κB activation in RAW264.7 cells induced by LPS and CpG DNA (CPG). Wherein Figure 28a shows the inhibition of KB on up-regulation of NF-κB p50 subunit in RAW264.7 cell nucleus induced by LPS and CpG DNA (CPG); Figure 28b shows the inhibition of KB on up-regulation of NF-κB p65 subunit in RAW264.7 cell nucleus induced by LPS and CpG DNA (CPG); and Figure 28c shows assay of KB inhibition on NF-κB activation in RAW264.7 cells induced by LPS and CpG DNA (CPG) using a luciferase reporter gene assay. The symbol ** in Figure 28 means p<0.01 vs LPS or CpG DNA;

Figure 29 shows KB inhibition on up-regulated expression of TLR4, TLR9 and MyD88, and KB inhibition on activation of NF-κB, in RAW264.7 cells stimulated by LPS and CpG DNA (CPG). Wherein Figure 29a shows KB inhibition on up-regulated expression of TLR4 and TLR9 mRNA in RAW264.7 cells induced by LPS and CpG DNA (CPG); Figure 29b shows KB inhibition on up-regulated expression of MyD88 mRNA in RAW264.7 cells induced by LPS and CpG DNA (CPG); and Figure 29c shows KB inhibition on activation of NF-κB in RAW264.7 cells induced by LPS and CpG DNA (CPG);

Figure 30 shows the influence of the combination of KB with LPS or CpG DNA (CPG) on vitality of RAW264.7 cells and murine peritoneal macrophages. Wherein Figure 30a shows the influence of KB on vitality of RAW264.7 cells; Figure 30b shows the influence of the combination of KB with LPS or CpG DNA (CPG) on vitality of RAW264.7 cells; Figure 30c shows the influence of KB on vitality of murine peritoneal macrophages; and Figure 30d shows the influence of the combination of KB with LPS or CpG DNA (CPG) on vitality of murine peritoneal macrophages.

Figure 31 shows the observation of KB protection (dose-dependent relationship) on mice challenged by lethal dose of heat-killed Escherichia coli. Wherein Figure 31 a shows the protection of single dose of KB (30 mg/kg) on mice challenged by lethal dose of heat-killed Escherichia coli. ; Figure 31 b shows the protection of single dose of KB (15, 30 and 60 mg/kg) on mice challenged by lethal dose of heat-killed Escherichia coli. ; Figure 31c shows the protection of multiple dosing of KB (1.25, 2.5 and 5 mg/kg) on mice challenged by lethal dose of heat-killed Escherichia coli. In Figure 31, the symbol * means p<0.05, and ** means p<0.01 vs E.coli. (EC);

Figure 32 shows the therapeutic action of KB to mice challenged by sublethal dose of heat-killed Escherichia coli. Wherein Figure 32a shows the influence of KB on LPS levels in plasma of mice challenged by sublethal dose of heat-killed Escherichia coli., and Figure 32b shows the influence of KB on TNF-α levels in serum of mice challenged by sublethal dose of heat-killed Escherichia coli. In Figure 32, the symbol * means p<0.05, and ** means p<0.01 vs E.coli. (EC);

Figure 33 shows the observation of KB protection (time-dependent relationship) on mice challenged by lethal dose of heat-killed Escherichia coli. In Figure 33, the symbol * means p<0.05, and ** means p<0.01 vs E.coli. (EC);

Figure 34 shows the influence of KB on major organ pathological morphous of mice. Wherein Figure 34a shows the lung morphology of mice after KB injection; Figure 34b shows the liver morphology of mice after KB injection; Figure 34c shows the kidney morphology of mice after KB injection; Figure 34d shows the cardiac muscle morphology of mice after KB injection.


DETAILED DESCRIPTION



[0018] Because LPS and CpG DNA are key factors inducing sepsis and autoimmune disease, antagonistic activity on LPS and CpG DNA can reflect preventive and therapeutic effects of certain drugs to sepsis and autoimmune disease. The research models selected in the detailed description are all used to evaluate the binding and antagonistic activity of KA and KB on LPS and CpG DNA, and to reflect treatment effect of KA and KB to sepsis and autoimmune disease. The present invention will be further descripted through following embodiments. It should be pointed out that the following embodiments are intended to illustrate rather than limit the disclosure.

[0019] The source of traditional Chinese herbs, reagent and materials in the detailed description

1. The source of 114 kinds of traditional Chinese herbs: name and origin, see Table 1



[0020] 
Table 1
Name and origin of 114 kinds of traditional Chinese herbs
Latin nameOriginLatin nameOriginLatin nameOrigin
Holboellia latifolia Wall. Sichuan Province Cinnamomum cassia Presl Guangxi Province Fraxinus rhynchophylla Hance Sichuan Province
Patrinia scabiosaefolia Fisch. Sichuan Province Piper kadsura (Choisy) Ohwi Zhejiang Province Gentiana macrophylla Pall. Gansu Province
Lobelia chinensis Lour. Sichuan Province Nelumbo nucifera Gaertn. Sichuan Province Artemisia annua L. Hubei Province
Scutellaria barbata D. Don Sichuan Province Phellodendron chinese Schneid. Sichuan Province Senecio scandens Buch.-Ham. Sichuan Province
Isatis indigotica Fort. (Isatidis Radix) Anhui Province Coptis chinensis Franch. Sichuan Province Polygonum bistorta L. Sichuan Province
Heterosmilax japonica Kunth Sichuan Province Scutellaria baicalensis Georgi Sichuan Province Cinnamomum cassia Presl Guangxi Province
Bletilla striata (Thunb.) Reichb.f. Sichuan Province Dioscorea bulbifera L. Hubei Province Sophora tonkinensis Gagnep. Sichuan Province
Pulsatilla chinensis (Bge.) Regel Jiangxi Province Sargentodoxa cuneata (Oliv.) Rehd et Wils. Sichuan Province Cornus officinalis Sieb. et Zucc. Guangxi Province
Oldenlandia diffusa (Willd.) Jiangxi Province Saxifraga stolonifera Curt. Sichuan Province Crataegus pinnatifida Bge. Hebei Province
Roxb.       var. major N. E. Br.  
Dictamnus dasycarpus Turcz. Liaoning Province Sophora japonica L. (Sophorae flos) Sichuan Province Cremastra appendiculata (D. Don) Makino Sichuan Province
Ampelopsis japonica (Thunb.) Makino Sichuan Province Sophora japonica L. (Sophorae fructus) Henan Province Phytolacca acinosa Roxb. Sichuan Province
Cynanchum atratum Bge. Anhui Province Cannabis saliva L. Sichuan Province Cnidium monnieri (L.) Cuss. Guangdong Province
Mentha haplocalyx Briq. Zhejiang Province Platycodon grandiflorum (Jacq.) A.DC. Hebei Province cimmicifuga heracleifolia Kom. Sichuan Province
Bupleurum chinense DC. Sichuan Province Schizonepeta tenuifolia Briq. Sichuan Province Punica granatum L. Sichuan Province
Amomum tsao-ko Crevost et Lemarie Guangdong Province Fagopyrum dibotrys (D.Don) Hara Sichuan Province Prunus persica (L.) Batsch Sichuan Province
Dichroa febrifuga Lour. Sichuan Province Lonicere japonica Thunb. Sichuan Province Asparagus cochinchinensis (Lour.) Merr. Henan Province
Platycladus orientalis (L.) Franco Sichuan Province Tinospora sagittata (Oliv.) Gagnep. Sichuan Province Trichosanthes kirilowii Maxim. Hunan Province
Artemisia argyi Lévl. et Vant. Sichuan Province Cassia obtusifolia L. Hubei Province Semiaquilegia adoxoides (DC.) Makino Sichuan Province
Fritillaria cirrhosa D. Don Sichuan Province Chrysanthemum morifolium Ramat. Zhejiang Province Clematis chinensis Osbeck Sichuan Province
Iris tectorum Maxim. Hubei Province Aspongopus chinensis Dallas Sichuan Province Prunus mume (Sieb.) Sieb. et Zucc. Sichuan Province
Andrographis paniculata (Burm.f.) Nees Guangdong Province Sophora flavescens Ait. Sichuan Province Scrophularia ningpoensis Hemsl. Sichuan Province
Sdeum sarmentosum Bunge Sichuan Province Tripterygium wilfordii Hook.f. Sichuan Province Terminalia chebula Retz. (Purchased from Guangdong Province) Guangdong Province
Paeonia Inner Nelumbo Sichuan Prunella vulgaris Sichuan
lactiflora Pall. Mongolia nucifera Gaertn. Province L. Province
Isatis indigotica Fort. (Isatidis folium) Anhui Province Forsythia suspensa (Thunb.) Vahl Henan Province Asaruin heterotropoides Fr. Schmidt var. mandshuricum (Maxim.) Kitag. Liaoning Province
Rheum palmatum L. Sichuan Province Gentiana manshurica Kitag. Jilin Province Commelina communis L. Sichuan Province
Salvia miltiorrhiza Bge. Gansu Province Solanum nigrum L. Sichuan Province Brucea javanica (L.) Merr. Sichuan Province
Hypericum japonicum Thumb. Sichuan Province Rhaponticum uniflorum (L.) DC. Sichuan Province Chrysanthemum indicum L. Sichuan Province
Kochia scoparia (L.) Schrad. Sichuan Province Phragmites communis Trin. Sichuan Province Houttuynia cordata Thumb. Sichuan Province
Lycii cortex Gansu Province Lasiosphaera fenzlii Reich. Inner Mongolia Stellaria dichotoma L. var. lanceolata Bge. Inner Mongolia
Sanguisorba officinalis L. Jiangsu Province Portulaca oleracea L. Sichuau Province Artemisia capillaris Thunb. Shaanxi Province
Eugenia caryophyllata Thunb. Yunnan Province Verbena officinalis L. Sichuan Province Arnebia enchroma (Royle) Johnst. Liaoning Province
Cassia angustifolia Vahl Sichuan Province Ilex pubescens Hook.et Arn. Sichuan Province Viola yedoensis Makino Sichuan Province
Stephania tetrandra S. Moore Guangdong Province Paeonia suffruticosa Andr. Henan Province Citrus aurantium L. Sichuan Province
Poria cocos (Schw.) Wolf Hubei Province Folium Hibisci Mutabilis Sichuan Province Terminalia chebula Retz. (Purchased from Yunnan Province) Yunnan Province
Aconitum carmichaelii Debx. Sichuan Province Equisetum hiemale L. Shaanxi Province Paris polyphylla Sm. Sichuan Province
Alpihia officinarum Hance Guangxi Province Rumex nepalensis Spreng. Sichuan Province Anemarrhena asphodeloides Bge. Inner Mongolia
Pueraria lobata (Willd.) Guangxi A Province Arctium lappa L. Sichuan Province Gardenia jasminoides Ellis Sichuan Province
Ohwi Dryopteris crassirhizoma Nakai Sichuan Province Taraxacum mongolicum Hand.-Mazz. Hebei Province Gleditsia sinensis Lam. Sichuan Province

2. Reagent and meterials



[0021] Absolute ethyl alcohol (EtOH) and disodium hydrogen phosphate (Na2HPO4) were purchased from Chongqing Chuandong (Group) Chemical Factory Co. Ltd.; AB-8 Macroporous adsorption resin and D001 cation exchange gel column were purchased from Chemical Plant of NanKai University in Tianjin; Trifluoroacetic acid (TFA) was purchased from Tianjin Guangfu Fine Chemical Research Institute; methanol (MeOH) was purchased from Hyclone company (USA); GIBCO®DMEM culture medium was purchased from Invitrogen company (USA); fetal calf serum (NCS) was purchased from Hyclone company (USA); PBS (20 mM, pH 7.2) was purchased from WuHan Boster Biological Technology., LTD; hydrochloric acid (HCl) was purchased from Chongqing Chuandong chemical plant (Group) Co., Ltd.; RAW264.7 cells and reference strain Escherichia coli. were purchased from American Type Culture Collection (ATCC); LPS, Poly I:C, polymyxin B (PMB), lipid A, FITC-labeled LPS, 5-FAM CpG DNA and 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di phenytetrazoliumromide (MTT) was purchased from Sigma company (USA); Pam3csk4 was purchased from Invitrogen company (USA); recombinant murine TNF-α and IL-6 were purchased from PeproTech company (USA); the biosensor cuvette and immobilized reagents are purchased from Thermo company (USA); Tachypleus amebocyte lysate and LPS-free water were purchased from A&C Biological Ltd, Zhanjiang, China; murine TNF-α and IL-6 ELISA Kits were purchased from R&D company (USA); NF-κB ELISA Kit was purchased from Active Motif company (Japan); real-time PCR Kit was purchased from TOYOBO company (Japan); antibody was purchased from Santa Cruz company (USA) and CST company (USA); ECL Western Blotting Kit was purchased from pierce company (USA); luciferase reporter gene plasmid and Kit were purchased from Promega company (USA); KM mice (SPF grade) was purchased from the Experimental Animal Center of the Third Military Medical University.

Embodiment 1: Binding assay of 114 kinds of traditional Chinese medicine decoction with lipid A and CpG DNA


1.1. Methods



[0022] Immobilization of lipid A and CpG DNA: Using Optically-Based Affinity Biosensors technology, Lipid A, the biologic active centres of LPS, and CpG DNA were respectively, immobilized on the reacting surfaces of cuvettes in an IAsys plus affinity biosensor according to the manufacturer's instructions of IAsys Affinity Sensor. The end of hydrophobic side chain of lipid A was immobilized on cuvette with hydrophobic surface, and the phosphate group (active group of lipid A) at the other end was floating and exposing to the outside, which act as target spot of binding with active constituents for disease treatment in traditional Chinese medicine. The active constituents in solution were binded to lipid A through electrostatic interaction. Biotinylated CpG DNA was immobilized on the surface of a biotin cuvette by linking to avidin, which had been coated on the surface of a biotin cuvette, and then the unlabeled group of CpG DNA was floating and exposing to the outside, which act as target spot of binding with active constituents for disease treatment in traditional Chinese medicine. The active constituents in solution were binded to CpG DNA through the electrostatic interaction and embedment.

[0023] Detection of the aqueous herbal extract: The crude drugs of 114 traditional Chinese herbs were pulverized. 1 g of each powder was added with 10 ml distilled water, boiled at 100 °C for 1.5 h, centrifuged at 4000 rpm for 20 min, filtrated and then collected the supernatant. 5 µl of aqueous herbal extracts of each herb were used to detect their binding with lipid A or CpG DNA. Here are the steps: ①Binding reaction: 45 µl PBS was added in cuvette; then 5 µl samples was added in cuvette; liquid were draw-out after binding response reach a plateau; ②Dissociation: Cuvette was washed thrice in 50 µl PBS; liquid were draw-out after dissociation reach a plateau; ③ Regeneration: Cuvette was washed thrice in 50 µl 0.1 N HCl; liquid were draw-out after regeneration reach a plateau; ④ Cuvette was washed thrice in 50 µl PBS; next cycle was started to detect new sample after curves back to baseline levels and smoothed. Data analysis was performed using the FASTplot software after detection finished.

1.2. Results:



[0024] In the 114 kinds of traditional Chinese herbs, 6 kinds of herbs such as Lycii cortex have high affinity with both lipid A and CpG DNA, among which, Lycii cortex has the highest affinity. The results suggest that Lycii cortex has greater potential of containing active constituents antagonizing LPS and CpG DNA than other traditional Chinese herbs, so it was selected as study object of extraction and separation. The results were shown in Figure 1. Wherein Figure 1 a is a response curve of immobilization of lipid A; Figure 1b is a response curve of immobilization of CpG DNA; Figure 1c shows binding reaction of lipid A with Lycii cortex and other 6 kinds of traditional Chinese herbs; Figure 1d shows binding reaction of CpG DNA with Lycii cortex and other 6 kinds of traditional Chinese herbs.

Embodiment 2: Extraction and separation of Kukoamine A and Kukoamine B, active constituents antagonizing LPS and CpG DNA in Lycii cortex


2.1 Separation via macroporous adsorption resins and screening of the active site


2.1.1 Methods:



[0025] 500 g Lycii cortex was added with 5L distilled water, soaked for 24 h, boiled at 100 °C for 1 h, filtered by coarse filter paper, and centrifuged at 8000 rpm/min for 30 min, and the supernatant was collected and concentrated to 1 L under reduced pressure. The supernatant was loaded onto AB-8 Macroporous adsorption resin, and eluted with distilled water and gradient ethanol (10%, 20%, 40% and 100%) successively. The eluted fractions were separately collected, and lyophilized after concentrated under reduced pressure. Five constituents were obtained, and named CL-1 to -5 according to their elution order. CL constituents were separately dissolved in PBS to make 1.0 mg/ml solution, 5 µl of which were loaded. Their binding activity with lipid A and CpG DNA were detected according to methods of embodiment 1.

.1.2 Results:



[0026] 2Among the 5 constituents, CL-4 has the highest affinity with lipid A and CpG DNA. The results suggest that CL-4 is the main active site of CL constituents, therefore, CL-4 was selected for further separation. The results were shown in Figure 2. Wherein Figure 2a is the chromatogram of constituent separation of CL-1 to -5; Figure 2b shows binding reaction of CL-1 to -5 constituents with lipid A; Figure 2c shows binding reaction of CL-1 to -5 constituents with CpG DNA.

2.2 Separation via cation exchange gel column and screening of the active site


2.2.1 Methods:



[0027] CL-4 lyophilization powder was diluted into ultrapure water to make 100 mg/ml solution, filtered by a 0.45 µm filter membrane, loaded onto D001 cationic exchange gel column, and eluted with distilled water, 0.3 M Na2HPO4 and 0.5 M Na2HPO4 successively. The eluted fractions were separately collected, and lyophilized after concentrated under reduced pressure. Three constituents were obtained, and named CL-4a, -4b and -4c according to their elution order. CL-4 constituents were separately dissolved in PBS to make 1.0 mg/ml solution, 5 µl of which were loaded. Their binding activity with lipid A and CpG DNA were detected according to methods of embodiment 1.

2.2.2 Results:



[0028] Three constituents were obtained, CL-4a, -4b and -4c. Among which CL-4b has the highest affinity with lipid A and CpG DNA. The results were shown in Figure 3. Wherein Figure 3a is chromatogram of constituents separation of CL-4a, -4b and -4c; Figure 3b shows binding reaction of CL-4 constituents with lipid A; Figure 3c shows binding reaction of CL-4 constituents with CpG DNA.

2.3 Identification of CL-4b antagonistic activities on LPS or CpG DNA


2.3.1 LPS-neutralization of CL-4b in vitro


2.3.1 Methods:



[0029] CL-4b was dissolved into LPS-free water to make 8 µg/ml solution, and incubated with equal volume of LPS (1 ng/mL) at 37°C for 30 min. Subsequently, 100 µL mixed solution of CL-4b and LPS was added with equal volume of the quantitative TAL reagents dissolved in LPS-free water, gently shaked to mix the contents, and reacted at 37°C for 60 min in kinetic tube reader. The agglutination of TAL reagent induced by the existence of non-neutralized LPS was measured. The mixture of LPS and equal volume of LPS-free water act as positive control. Each group contained three repeated tubes. The result was expressed in EU/ml, the endotoxin unit of LPS. Operation was performed according to the manufacturer's instructions of EDS-99 Bacterial Endotoxin Detecting system.

2.3.1.2 Results:



[0030] Cl-4b can not lead to TAL agglutination by itself, but it can significantly reduce the agglutination induced by LPS after incubated with LPS for 30 min. The result suggests that CL-4b has neutralizing activity on LPS. The results were shown in Figure 4.

2.3.2 Inhibition of CL-4b on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA


2.3.2.1 Methods:



[0031] RAW 264.7 cells were adjusted to 1×106/ml in DMEM supplemented with 10% NCS (v/v), transferred into 96-well plate (200 µl per well), cultured at 37 °C in a 5% CO2 humidified incubator for 4 h, and loaded after cells attachment; for the purpose of the experiment three groups were established: medium group, stimulation group and drug treatment group, and each group contained three repeated wells; medium group was added with no reagent; stimulation group was added with LPS (final concentration of 100 ng/ml) or CpG DNA (final concentration of 10 µg/ml); drug treatment group was added with CL-4b (final concentration of 200 µg/ml), as well as LPS (final concentration of 100 ng/ml) or CpG DNA (final concentration of 10 µg/ml); cells were cultured at 37 °C in a 5% CO2 humidified incubator for 24 h, and the supernatant was collected for further detection. Detections of TNF-α and IL-6 were performed according to the manufacturer's instructions of ELISA kit, and the result was expressed by means of mean ± standard deviation.

2.3.2.2 Results:



[0032] CL-4b does not induce the release of TNF-α and IL-6 in RAW264.7 cell by itself, but it can significantly reduce the release of of TNF-α and IL-6 in RAW264.7 cell induced by LPS and CpG DNA. The result suggested that CL-4b has antagonistic activity on LPS or CpG DNA in vitro. The results were shown in Figure 5. Wherein Figure 5a shows the inhibition of CL-4b on the release of TNF-α and IL-6 in RAW264.7 cells induced by LPS, and Figure 5b shows the inhibition of CL-4b on the release of TNF-α and IL-6 in RAW264.7 cells induced by CpG DNA.

2.3.3 CL-4b protection on mice challenged by lethal dose of heat-killed Escherichia coli


2.3:3.1 Methods:



[0033] Praparation of heat-killed Escherichia coli (E. coli) ATCC 35218: Bacteria culture was performed according to Clinical Laboratory Procedures. Single bacterial colony of E. coli from LB agar plates were picked and transferred into 10 mL sterile liquid of LB broth using a sterile inoculating loop, and cultivated at 37°C in a shaker (250 rpm). After medium become turbid, these culture medium were then transferred to 2000 mL of fresh LB medium and cultivated at 37°C in a shaker (250 rpm) for 12 h. The suspension was collected, transferred into 1000 ml centrifuge tube, and centrifuged at 5000 rpm for 15 min. The supernatant was discarded. The bacteria were collected, washed and resuspended into sterile saline, and then centrifuged again under the same condition. Above-mentioned process was repeated thrice. The bacteria pellet was resuspended with a pipet in 50 ml sterile saline, transferred into 100 ml saline bottle, and boiled in electric furnace for 30 min. Then the suspension of heat-killed Escherichia coli was obtained. The suspension of E. coli was diluted by 100 fold, and measured OD value at 600 nm on nucleic acid protein analyzer. Conversion was made according to the regression equation of OD value and concentration, and the suspension was diluted according to the conversion result. Then the operating fluids for mice injection were obtained.

[0034] Observation of CL-4b protection on mice challenged by heat-killed Escherichia coli: A total of 40 Kunming mice (18∼20 g), half male and half female, were divided into three groups randomly: CL-4b control group, heat-killed E. coli group and CL-4b treatment group. Each group has 10 mice, half male and half female. CL-4b control group was injected with CL-4b (60 mg/kg) and sterile saline; heat-killed E. coli group was injected with heat-killed Escherichia coli (1.0×1010 CFU/ml) and sterile saline; CL-4b treatment group was injected with CL-4 (60 mg/ml) at 10 min after heat-killed E. coli injection. The injection volum of each solution was 200 µl per 20 g body weight via tail vein. Injection volume of each mouse was 200 µl per 20 g body weight. The general status and mortality rate of mice were observed for 7 days, and survival differences between CL-4b control group and CL-4b treatment group were compared.

2.3.3.2 Results:



[0035] Nothing but CL-4b (60 mg/kg) and sterile saline have no influence on general status and survival rates of mice; The motality rate of heat-killed E. coli group was 90% at 3 days; Intervention with CL-4b (60 mg/kg) while injecting heat-killed E. coli can decrease the motality rate of mice challenged by heat-killed E. coli to 50%. The results show that CL-4b has a significant protective effect on mice challenged by lethal dose of heat-killed E. coli. The results were shown in Figure 6.

2.4 Isolation by Preparative High-Performance Liquid Chromatography


2.4.1 Methods:



[0036] The choice of chromatographic conditions: An Agilent Technology 1200 Series analytical HPLC system was used for composition analysis; CL-4b was diluted with mobile phase (A (0.1% TFA): B (MeOH) = 80:20, v/v) to make 0.5 mg/ml solution; the analysis was carried out with an Agilent XDB-C18 analytical column (150 mm×4.6 mm, 5 µm) packed with the octadecyl silane chemically bonded silica; the detection wavelength was 280 nm; flow rate was at 1 ml/min; column temperature was 25°C; sample size was 10 µl;

[0037] Preparation of high performance liquid chromatography: An Agilent Technology 1100 Series preparative HPLC system was used for isolation; CL-4b was diluted with mobile phase (A (0.1% TFA): B (MeOH) = 80:20, v/v) to make 20 mg/ml solution; the analysis was carried out with an Agilent KF-C18 column (200 mm×20 mm, 10 µm) packed with the octadecyl silane chemically bonded silica; the detection wavelength was 280 nm; flow rate was at 10 ml/min; column temperature was room temperature; sample size was 20 ml; the Chromatographic peak eluates of retention time 16 to 20 and 20 to 30 min, were separately collected and dried under reduced pressure; two components were obtained and named CL-4b1 and CL-4b2 according to the order of their retention time; CL-4b1 and CL-4b2 were dissolved in PBS to make 1.0 mg/ml solution, 5 µl of which were loaded onto HPLC; their binding activity with lipid A and CpG DNA were detected according to methods of embodiment 1.

2.4.2 Results:



[0038] Two major components, CL-4b1 and CL-4b2, were obtained by HPLC analysis and preparation. The chromatogram was shown in Figure 7. Wherein Figure 7a is a HPLC diagram of CL-4b1 component, Figure 7b is a HPLC diagram of CL-4b2 component. These two components were preliminarily recognized as single compound by peak purity analysis in HPLC.

2.5 Identification of the chemical structure of CL-4b1 and CL-4b2


2.5.1 Methods: CL-4b1 and CL-4b2 were analyzed by UV spectrum, IR spectrum, NMR spectrum and mass spectrum.


2.5.2 Results:



[0039] CL-4b1 and CL-4b2 are both pale yellow crystals. UV spectrum detection shows that the absorption peaks (λmax) of the two components are both at point 281 nm (methanol); and results of ESI-MS of the two components are both [M+H]+ m/z 531, which suggests that they are a pair of isomeride. The results of NMR spectrum are shown in Table 2:
Table 2
NMR spectrum detection results of kukoamine A and kukoamine B
 Kukoamine AKukoamine B
CHCH
2 t 34.9 3.25 38.50 3.18
3 m 25.6 1.75 28.41 1.68
4 t 44 2.79 47.46 2.55
6 t 46.5 2.88 50.10 2.75
7 m 22.4 1.75 25.75 1.48
8 m 22.4 1.75 27.97 1.37
9 t 46.5 2.88 50.56 3.23
11 t 44 2.79 45.55 3.38
12 m 25.6 1.75 27.88 1.82
13 t 34.9 3.25 39.78 2.82
1' - 131.9   135.9  
2' d 115.2 6.66 119.1 6.76
3' - 144.1   146.8  
4' - 142.7   145.2  
5' d 115.4 6.69 119.2 6.83
6' dd 119.8 6.55 123.6 6.67
7' t 30.3 2.68 33.28 2.82
8' t 36.6 2.51 39.78 2.55
9' - 174.8   179.2  
1" - 131.9   136.5  
2" d 115.2 6.66 119.3 6.78
3" - 144.1   146.9  
4" - 142.7   145.3  
5" d 115.4 6.69 119.4 6.84
6" dd 119.8 6.55 123.8 6.68
7" t 30.3 2.68 33.65 2.82
8" t 36.6 2.51 37.00 2.68
9" - 174.8   178.9  


[0040] By structural analysis, CL-4b1 was identified as Kukoamine A (KA), and CL-4b2 was identified as Kukoamine B (KB).

Embodiment 3: Affinity detection of KA and KB with lipid A and CpG DNA in vitro


3.1 Methods:



[0041] KA and KB were separately dissolved to make 100 µM operating solution; 5 µl of the solution was loaded; their binding activity with lipid A and CpG DNA were detected according to methods of embodiment 1.

3.2 Results:



[0042] KA and KB both have high affinity with lipid A and CpG DNA. The results were shown in Figure 8. Wherein Figure 8a shows the affinity detection of KA and KB with lipid A, and Figure 8b shows the affinity detection of KA and KB with CpG DNA.

Embodiment 4: Neutralizing activity of KA and KB with LPS in vitro


4.1 Methods:



[0043] KA and KB(1, 2 and 4 µg/ml) were separately mixed with equal volume of LPS(2.0 ng/ml) and pre-incubated at 37°C for 30 min; LPS control group was added with equal volume of nonpyrogenic water; LPS value was detected by kinetic turbidimetric limulus test after incubation; detection of each concentration was repeated three times; LPS content was expressed by means of mean ± standard deviation; operation was performed according to the manufacturer's instructions of EDS-99 Bacterial Endotoxin Detecting system.

4.2 Results:



[0044] Both KA and KB has neutralizing activity with LPS. Statistical analysis showed that KA and KB have significant neutralizing activity with LPS(p<0.05 or p<0.01), and there is an obvious dose-dependent relationship between them, which suggests that KA and KB can antagonize LPS effectively and thus play a role in the prevention and treatment of sepsis and autoimmune disease. The results were shown in Figure 9.

Embodiment 5: Influence of KA and KB on the binding of fluorescently-labeled LPS and CpG DNA with RAW264.7 cells


5.1 Methods:



[0045] RAW264.7 cells were diluted to 1×106/ml in DMEM supplemented with 10%(v/v) NCS, added into 24-well cell culture plates, cultured at 37 °C in a 5% CO2 humidified incubator for 4 h, added with KA and KB(0, 200 µg/ml) after cells attachment, and then added with FITC-labeled LPS(final concentration of 400 ng/ml) and 5-FAM CpG DNA(final concentration of 10 µg /ml); at the same time, medium group without any reagent was established; subsequently, RAW264.7 cells were incubated for 30 min, washed thrice in PBS, resuspended with a pipet and transferred into EP tube, and immobilized with 4% paraform for 10 min; then cells were washed thrice in PBS, made into cell suspension, and detected by flow cytometry; the detections of each group were repeated thrice. Mean fluorescence intensity was expressed by means of Mean ± standard deviation.

5.2 Results:



[0046] KA and KB can significantly decrease the fluorescence intensity of LPS and CpG DNA (p<0.01) in RAW264.7 cells, which suggested that they can influence the binding of LPS and CpG DNA with RAW264.7 cells, effectively inhibite the excessive immune response induced by LPS and CpG DNA, prevent injury to the body, and thus play a role in the prevention and treatment of sepsis and autoimmune disease. The results were shown in Figure 10. Wherein Figure 10a shows the influence of KA and KB on the binding of fluorescently-labeled LPS with RAW264.7 cells, and Figure 10b shows the influence of KA and KB on the binding of fluorescently-labeled CpG DNA with RAW264.7 cells.

Embodiment 6: Influence of KA and KB on release of TNF-α in RAW264.7 cells induced by LPS and CpG DNA


6.1 Methods:



[0047] RAW264.7 cells were diluted to 1×106/ml in DMEM supplemented with 10% (v/v) NCS, added into 96-well plates (200 µl per well), and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h until cells adhere to the wall; culture medium were replaced with fresh culture medium, added with KA and KB (final concentrations of 0, 50 and 100 ng/ml), and added with LPS (final concentration of 100 ng/ml) and CpG DNA (final concentration of 10µg/ml); at the same time, medium group without any reagent was established; subsequently, RAW264.7 cells were incubated for 4 h; and the supernatant was collected for further detection; dectection of the TNF-α concentration was performed according to the manufacturer's instructions of ELISA kit. Result was expressed by means of mean ± standard deviation.

6.2 Results:



[0048] KA and KB can inhibit the release of TNF-α induced by LPS and CpG DNA in a dose-dependent manner, which has significant difference compared with control group (p<0.01). Extended release of a large amount of TNF-α play an important role in the pathological damage in sepsis and autoimmune disease, therefore inhibition on TNF-α release can effectively prevent and cure sepsis and autoimmune disease. The results were shown in Figure 11. Wherein Figure 11 a shows the influence of KA and KB on the release of TNF-α in RAW264.7 cells induced by LPS, Figure 11b shows the influence of KA and KB on the release of TNF-α in RAW264.7 cells induced by CpG DNA.

Embodiment 7: Detection of influence of KA and KB on cell vitality (MTT assay)


7.1 Methods:



[0049] MTT assay were adoped for cell vitality detection; RAW264.7 cells were diluted to 1×106/ml in DMEM medium, added into 96-well plates(200 µl per well), and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h; treatment group was successively added with KA and KB (final concentration of 200µg/ml); no reagent was added in medium group; each group has 6 parallel wells; subsequently, RAW264.7 cells were cultured for 24 h; the supernatant was discarded; each well was added with 180 µl culture medium and 20 µl MTT solution(5mg/ml), and cultured for 4 h; the supernatant was removed; 150 µl of dimethyl sulphoxide was added into each well; the 96-well plates were shook for 10 min for the dissolution of the crystals; RAW264.7 cells vitality was expressed as absorbance values at 550 nm (OD550) of each well; the absorbance values between treatment group and medium group were compared.

7.2 Results:



[0050] Result of MTT assay shows that KA and KB (200 µg/ml) have no influence on RAW264.7 cells vitality (p>0.05), which suggests that inhibition of KA and KB (200 µg/ml) on the release of TNF-α in RAW264.7 cells is not induced by their cytotoxicity. The results were shown in Figure 12.

Embodiment 8: Antagonism of KA and KB on LPS and CpG DNA in vivo


8.1 Methods:



[0051] Supernatant of heat-killed E. coli was prepared according to 2.3.3 items of embodiment 2; absorbance values of the supernatant were assayed at 600 nm (OD600 value 1.0≈1.0 ×1010 CFU/ml); a total of 84 Kunming mice, half male and half female, were divided into three groups randomly: heat-killed E. coli control group, KA (40 mg/kg) plus heat-killed E. coli group and KB (40 mg/kg) plus heat-killed E. coli group; each group has 28 mice; after animals were weighed, heat-killed E. coli control group was injected with heat-killed E. coli(1.1 ×1010 CFU/ Kg); the other two groups were respectively injected with KA or KB (40 mg/kg) at 10 min after injection of heat-killed E. coli(1.1 ×1010 CFU/ Kg); the total injection of each animal was 200 µl per 20 g body weight; orbital venous blood of mice was collected at time point of 0, 2, 4, 8, 12, 24, 48 and 72h after injection; LPS level was assayed by kinetic turbidimetric limulus test, and TNF-α was assayed by ELISA.

8.2 Results:



[0052] Heat-killed E. coli has no proliferative activity, but it contains large amount of LPS and CpG DNA, which can simulate the stimulation of LPS and CpG DNA in vivo. The LPS and TNF-α level in mice blood of heat-killed E. coli control group began to increase rapidly 4 h after injection, and fell back to initial state within 24 to 48 h. As compared with heat-killed E. coli control group, the LPS and TNF-α level in mice blood of KA or KB treatment group at various time points were significantly decreased (p<0.05 or p<0.01). The results suggested that, KA and KB can effectively antagonize LPS and CpG DNA, inhibit extended release of a large amount of TNF-α through inhibiting the stimulation of LPS and CpG DNA, and then effectively prevent and cure sepsis and autoimmune disease. The results were shown in Figure 13. Wherein Figure 13a shows the influence of KA and KB on LPS level in blood of mice challenged by E. coli, and Figure 13b shows the influence of KA and KB on TNF-α level in blood of mice challenged by E. coli.

Embodiment 9: Assessment of affinity constants (dissociation equilibrium constant) of KB with LPS and CpG DNA


9.1 Methods:



[0053] KB was separately diluted with PBS to make solutions of 0.25, 0.5, 1, 2 and 4 µM; 5 µl of each solution was separately loaded; binding reaction of KB of various concentration with LPS and CpG DNA was assayed according to the methods in embodiment 1. The dissociation equilibrium constant (KD) of KB with LPS and CpG DNA was calculated using the IAsys FASTfit software.

9.2 Results:



[0054] The dissociation equilibrium constant (KD) of KB with LPS and CpG DNA is respectively 1.24 µM and 0.66 µM. The results were shown in Table 3.
Table 3
Dissociation equilibrium constant (KD) of KB with LPS and CpG DNA
 association rate constant (kass)dissociation rate constant (kdiss)dissociation equilibrium constant (KD=kass / kdiss)
LPS 0.0204448 ± 0.0031071 16531.5 ± 648.0 1.23672×10-6 M
CpG DNA 0.0419045 ± 0.0031342 63119.0 ± 672.4 6.63897×10-7 M

Embodiment 10: Detection and comparation of binding reaction of polymyxin B (PMB) with LPS and CpG DNA


10.1 Methods:



[0055] KB and PMB were separately diluted with PBS to make a 4 µM solution; 5 µl of each solution was loaded respectively; affinity of KB and PMB with LPS and CpG DNA was respectively assayed according to the methods in embodiment 1.

10.2 Result:



[0056] PMB is an antagonistic drug of LPS. In biosensor detection, PMB has high affinity with LPS, and its binding force with LPS is almost 2 times as much as that of KB. But PMB almost has no binding effects on CpG DNA. However, KB has high affinity with CpG DNA, which suggests that KB can bind to both LPS and CpG DNA. The results were shown in Figure 14. Wherein Figure 14a shows the affinity detection of KB and PMB with LPS, and Figure 14b shows the affinity detection of KB and PMB with CpG DNA.

Embodiment 11: Detection and comparation of neutralizing activity of KB and PMB with LPS and CpG DNA


11.1 Methods:



[0057] KB and PMB were separately diluted with LPS-free water to make solutions of 0.5, 1, 2, 4, 8, 16, 32, 64 and 128 µM; according to the methods in embodiment 4, above solutions were separately mixed with equal volume of LPS (2 ng/ml), and neutralizing activity was assayed.

11.2 Results:



[0058] LPS-neutraliztion of KB is similar to PMB, which also presents a dose-dependent relationship. But inhibition effect of KB is weaker than PMB. Half inhibitory concentration (IC50) of KB and PMB on LPS (2 ng/ml) was 14.93 µM and 4.80 µM separately. The results were shown in Figure 15.

Embodiment 12: Inhibition of KB on the release of TNF-α and IL-6 in RAW264.7 cells induced by LPS and CpG DNA


12.1 Methods:



[0059] According to the method in embodiment 6, KB was dissolved in DMEM supplemented with 10%(v/v) NCS, subsequently transferred into Culture medium of RAW264.7 cells to achieved final concentrations of 100 and 200 µM, added with LPS (final concentration of 100 ng/ml) and CpG DNA (final concentration of 10 µg /ml), incubated for 24 h, and then collected supernatant; the concentration of TNF-α and IL-6 of each group was detected according to the manufacturer's instructions of ELISA kit; result was expressed by means of mean ± standard deviation.

12.2 Results:



[0060] KB can inhibit the release of TNF-α and IL-6 induced by both LPS and CpG DNA. The results were shown in Figure 16. Wherein Figure 16a shows the inhibition of KB on the release of TNF-α in RAW264.7 cells stimulated by LPS and CpG DNA, and Figure 16b shows the inhibition of KB on the release of IL-6 in RAW264.7 cells stimulated by LPS and CpG DNA.

Embodiment 13: Comparation of the influence of KB and PMB on the release of TNF-α and IL-6 in RAW264.7 cells induced by LPS and CpG DNA


13.1 Methods:



[0061] According to the method in embodiment 6, KB and PMB were separately dissolved in DMEM supplemented with 10%(v/v) NCS, subsequently transferred into culture medium of RAW264.7 cells to achieved final concentrations of 50, 100 and 200 µM, and then added with LPS (final concentration of 100 ng/ml) and CpG DNA (final concentration of 10 µg /ml); RAW264.7 cells continued to be incubated; the supernatant were collected four hours later for TNF-α detection; the supernatant were collected 12 hours later for IL-6 detection; the concentration of TNF-α and IL-6 of each group was detected according to the manufacturer's instructions of ELISA kit; result was expressed by means of mean ± standard deviation.

13.2 Result:



[0062] KB can inhibit the release of TNF-α and IL-6 induced by both LPS and CpG DNA, and PMB can only inhibit the release of TNF-α and IL-6 induced by LPS. The results were shown in Figure 17. Wherein Figure 17a shows the inhibition of KB and PMB on the release of TNF-α in RAW264.7 cells stimulated by LPS; Figure 17b shows the inhibition of KB and PMB on the release of TNF-α in RAW264.7 cells stimulated by CpG DNA; Figure 17c shows the inhibition of KB and PMB on the release of IL-6 in RAW264.7 cells stimulated by LPS; Figure 17d shows the inhibition of KB and PMB on the release of IL-6 in RAW264.7 cells stimulated by CpG DNA.

Embodiment 14: Effect of KB on the release of TNF-α and IL-6 in murine peritoneal macrophages induced by LPS and CpG DNA


14.1 Methods:



[0063] Separation and culture of murine peritoneal macrophages: KM mice were killed by cervical dislocation and immediately immersed in 75% ethanol for skin degerming; then abdominal skin was aseptically cut open; precooling DMEM cell culture medium was slowly injected in exposed peritoneum with a 5 ml syringe; murine abdomen was gently massaged for sufficient cell collection; subsequently, DMEM was withdrew, transferred into 10 ml centrifuge tube, centrifuged at 500 rpm for 5 min, resuspended in DMEM supplemented with 10%(v/v) NCS, transferred into cell culture bottle, and then cultured at 37 °C in a 5% CO2 humidified incubator for 2 h; culture medium was replaced with fresh culture medium to remove unattached cells; over 95% of the remained cells were murine peritoneal macrophages, which continued to be cultured and proliferated.

Loading and detection:



[0064] According to the method in embodiment 6, KB and PMB were separately diluted in DMEM supplemented with 10%(v/v) NCS and transferred into culture medium of RAW264.7 cells to achieved final concentrations of 50, 100 and 200 µM; RAW264.7 cells continued to be incubated; the supernatant was collected four hours later for TNF-α detection; the supernatant at were collected 12 hours later for IL-6 detection; the concentration of TNF-α and IL-6 of each group was detected according to the manufacturer's instructions of ELISA kit; result was expressed by means of mean ± standard deviation.

14.2 Result:



[0065] Observed results were in basic agreement with observations in RAW264.7 cells. KB can inhibit the release of TNF-α and IL-6 induced by both LPS and CpG DNA, and PMB can only inhibit the release of TNF-α and IL-6 induced by LPS. The results were shown in Figure 18. Wherein Figure 18a shows the inhibition of KB and PMB on the release of TNF-α in murine peritoneal macrophages stimulated by LPS; Figure 18b shows the inhibition of KB and PMB on the release of TNF-α in murine peritoneal macrophages stimulated by CpG DNA; Figure 18c shows the inhibition of KB and PMB on the release of IL-6 in murine peritoneal macrophages stimulated by LPS; and Figure 18d shows the inhibition of KB and PMB on the release of IL-6 in murine peritoneal macrophages stimulated by CpG DNA.

Embodiments 15: Influence of KB on the mRNA expressions of TNF-α, IL-6, iNOS and COX-2 in RAW264.7 cells stimulated by LPS and CpG DNA


15.1 Methods:


Cells preparation:



[0066] Cells suspension was adjusted to 1×106/ml in DMEM supplemented with 10% (v/v) NCS; 2 ml of the above suspension was added into 6-well plates and cultured at 37 °C in a 5% CO2 humidified incubator for 2 h; for the purpose of experiment four groups were established: medium group, KB control group, stimulation group and KB treatment group; no reagent was added in medium group; KB control group was added with KB (200 µM); stimulation group was added with LPS (100 ng/ml) and CpG DNA (10 µg/ml); KB treatment group was added with KB (concentrations of 100 and 200 µM) in the meantime of adding LPS and CpG DNA; cells were cultured for 4 h and collected.

RNA extraction:



[0067] Supernatant was sucked and discarded; 1 ml tripure was added into each well and resuspended with a pipet to make cells completely lysed; the lysate was transferred into 1.5 ml EP tube and incubated at room temperature for 5 min to ensure completed separation of ribonucleoprotein complex; 0.2 ml chloroform was added into EP tube; tube cap was closed and mixed by inversion for 15 sec; EP tube was incubated at room temperature for 10 min until layering of the liquid in tube, then centrifuged at 12000 g at 4°C for 15 min; solution was separated into the three-phase; the upper solution (colorless liquid, approximately 0.4 ml) in EP tube was transferred into a new EP tube (DEPC treated); 0.5 ml isopropyl alcohol was added into EP tubes and the liquid was mixed by inversion for several times; EP tube was incubated at room temperature for 10 min to promote RNA precipitating, and centrifuged at 12000 g at 4°C for 10 min; the supernatant was discarded; RNA precipitate was added with 1 ml 75% ethanol, vortex washed, and centrifuged at 12000 g at 4°C for 10 min; then the supernatant was discarded; EP tube was dried at room temperature for 15 min to remove excessive ethanol; RNA precipitate was diluted with 20 µl ddH2O treated with DEPC, resuspended by pipetting in and out several times, incubated at 55 to 60°C for 10 min, and then stored at -70°C.

Reverse transcription:



[0068] Reverse-transcription reaction mixture (include: Rnase-free H2O, 10 µl; 5xRT buffer, 4 µl; dNTP mixture, 2 µl; RNase inhibitor, 1 µl; Oligo(dT)20, 1 µl; RNA, 1 µl; ReverTra Ace, 1 µl) was prepared on ice bath, mixed, incubated at 42°C for 1 h and at 99°C for 5 min, stored at -20 °C .

PCR amplification:



[0069] Primers were designed using Primer Premier 5 software by ourselves, and synthesized by Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. The relevant primer sequences are as follows
 Sequences
Mouse TNF-α Upstream primer: 5'-CAGGTTCTGTCCCTTTCACTCACT-3'
  Downstream primer: 5'-GTTCAGTAGACAGAAGAGCGTGGT-3
Mouse IL-6 Upstream primer: 5'-TGGAGTACCATAGCTACCTGGAGT 3'
  Downstream primer: 5'-TCCT-TAGCCACTCCTTCTGTGACT-3'
Mouse iNOS Upstream primer: 5'-TCCTACACCACACCAAAC-3'
  Downstream primer: 5'- CTCCAATCTCTGCCTATCC-3'
Mouse COX-2 Upstream primer: 5'-TAGCAGATGACTGCCCAACT-3'
  Downstream primer: 5'- CACCTCTCCACCAATGACCT-3'
Mouse β-actin Upstream primer: 5'-GGGAAATCGTGCGTGACATCAAAG-3'
  Downstream primer: 5'-CATACCCAAGAAGGAAGGC TGGAA-3'


[0070] Reaction mixture, which includes 1.5 µl cDNA, 10.0 µl 2×SYBR Green Master Mix, 0.5 µl upstream primer (10µM), 0.5 µl downstream primer (10 µM) and 7.5 µl RNase-free H2O, was added into 0.2 ml PCR tube. Amplification programs are as follows:
StepTemperaturestimeVelocityCycles
Initial denaturation 95°C 60 sec   1
PCR (Polymerase Chain Reaction) 95°C 30 sec   40
58 °C 30 sec  
72 °C 60 sec  
Melting Curve Assay 95°C 60 sec   1
54°C 60 sec   1
55°C 10 sec 0.05°C/sec 80


[0071] Results were expressed as CT value, and converted into ratio of β-actin, the internal reference items, according to 2-ΔΔCT methods. Result was expressed by means of mean ± standard deviation.

15.2 Results:



[0072] When murine RAW264.7 cells are not stimulated by LPS or CpG DNA, mRNA expressions of TNF-α, IL-6, iNOS and COX-2 are at low levels; LPS (100 ng/ml) or CpG DNA (10 µg/ml) can significantly up-regulated the expression of above inflammatory mediators in RAW 264.7 cells; KB (100, 200 µM) can significantly inhibit the mRNA expressions of TNF-α, IL-6, iNOS and COX-2 up-regulated by LPS and CpG DNA, and present a dose-dependent relationship with them. The results were shown in Figure 19. Wherein Figure 19a shows the inhibition of KB on the mRNA expression of TNF-α in RAW264.7 cells stimulated by LPS and CpG DNA; Figure 19b shows the inhibition of KB on the mRNA expression of IL-6 in RAW264.7 cells stimulated by LPS and CpG DNA; Figure 19c shows the inhibition of KB on the mRNA expression of iNOS in RAW264.7 cells stimulated by LPS and CpG DNA; and Figure 19d shows the inhibition of KB on the mRNA expression of COX-2 in RAW264.7 cells stimulated by LPS and CpG DNA.

Embodiment 16: Influence of KB on the mRNA expression of TNF-α and IL-6 in murine peritoneal macrophages stimulated by LPS and CpG DNA


16.1 Methods:



[0073] Influence of KB on the mRNA expression of TNF-α and IL-6 in murine peritoneal macrophages stimulated by LPS and CpG DNA was observed. Methods were the same as embodiment 15.

16.2 Results:



[0074] Observed results were in basic agreement with observations in RAW264.7 cells. KB (100, 200 µM) can significantly inhibit the mRNA expressions of TNF-α and IL-6 up-regulated by LPS and CpG DNA, and present a dose-dependent relationship with them. The results were shown in Figure 20. Wherein Figure 20a shows the inhibition of KB on the mRNA expression of TNF-α in murine peritoneal macrophages stimulated by LPS and CpG DNA, and Figure 20b shows the inhibition of KB on the mRNA expression of IL-6 in murine peritoneal macrophages stimulated by LPS and CpG DNA.

Embodiment 17: Observation of time and dose dependent effects of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA


17.1 Methods:



[0075] RAW264.7 cells was diluted to 1×106/ml in DMEM supplemented with 10% (v/v) NCS, transferred into 96-well plates (200 µl per well) and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h.
  1. (1) Observation of dose-dependent effects: For the purpose of experiment a medium group and a KB treatment group were established; each group included three repeated wells; medium group was added with no reagent; KB treatment group was added with KB (final concentrations of 12.5, 25, 50, 100 and 200 µM) in each well, and subsequently added with LPS (final concentration of 100 ng/ml) or CpG DNA (final concentration of 10 µg/ml); cells were cultured at 37 °C in a 5% CO2 humidified incubator for 12 h; the supernatant was collected for further detection; operations were performed according to the manufacturer's instructions of ELISA kit, and the result was expressed by means of mean ± standard deviation.
  2. (2) Observation of time-dependent effects: For the purpose of experiment a medium group, a stimulation group and a KB treatment group were established; each group contained three repeated wells; medium group was added with no reagent; stimulation group was added with LPS and CpG DNA; KB treatment group was added with LPS and CpG DNA, in the meantime added with KB (final concentration of 200 µM); cells continued to be cultured at 37 °C in a 5% CO2 humidified incubator; the supernatant at time point of 0, 2, 4, 8, 12 and 24 h after stimulation was seperately collected for further detection; detection of TNF-α concentration was performed according to the manufacturer's instructions of ELISA kit, and the result was expressed by means of mean ± standard deviation.

17.2 Results:



[0076] 
  1. (1) Observation of dose-dependent effects: After RAW264.7 cells were given with LPS (100 ng/ml) and CpG DNA (10 µg/ml), the release of TNF-α significantly increased, reaching 5710.85±98.03 pg/ml and 3126.39±237.67 pg/ml respectively. After KB treatment, the release of TNF-α in RAW264.7 cells was inhibited by varying degrees; Wherein at the KB concentration of 12.5 µM, the difference of RAW264.7 cells activation between KB treatment group and LPS group or CpG DNA group has no statistic significance (p>0.05); at the KB concentration of 25 µM and above, the inhibitory activity of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA significantly increased (p<0.05 or p<0.01). The inhibition of KB on TNF-α release in RAW264.7 cells induced by CpG DNA showed a dose-dependent relationship. The results were shown in Figure 21 a.
  2. (2) Observation of time-dependent effects: When RAW264.7 cells were not given with any treatment, only basal levels of TNF-α were detected at time point of 0, 2, 4, 8, 12 and 24 h, and there were no significant difference of TNF-α level between various time points. After stimulation by LPS (100 ng/ml) alone, TNF-α levels in supernatant began to increase rapidly at the 2-h time point, and became steady after 4-h time point. If cells were given with 200 µM KB at the meantime, TNF-α levels at various time points were all decreased. After stimulation by CpG DNA (10 µg/ml) alone, the time duration of TNF-α levels increasing in supernatant was basically consistent with LPS group, and TNF-α levels peaked at 12-h time point. If cells were given with 200 µM KB at the meantime, increased TNF-α levels induced by CpG DNA at various time points were all decreased. The antagonism of KB to CpG DNA was stronger than antagonism to LPS. The results were shown in Figure 21b and Figure 21c. Wherein Figure 21b shows the time-dependent effects of inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS, and Figure 21c shows the time-dependent effects of inhibition of KB on TNF-α release in RAW264.7 cells induced by CpG DNA.

Embodiment 18: Influence of different loading patterns on inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA


18.1 Methods:



[0077] RAW264.7 cells were diluted to 1×106/ml in DMEM supplemented with 10% (v/v) NCS, transferred into 96-well plates (200 µl per well) and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h.
  1. (1) KB was loaded after preincubation with LPS or CpG DNA: KB was diluted in DMEM supplemented with 10%(v/v) NCS to make 400 µM solution; 500 µl of the above KB solution or PBS were mixed with equal volume of LPS (200 ng/ml) or CpG DNA (20 µg/ml) respectively, and incubated at 37°C for 20 min and 40 min; RAW264.7 cells culture medium in the 96-well plate was replaced with the above solutions respectively, and continued to be cultured for 12 h; then the supernatant was collected; the concentration of TNF-α was detected according to the manufacturer's instructions of ELISA kit; result was expressed by means of mean ± standard deviation.
  2. (2) KB. was loaded at various time points: The time point of adding LPS (200 ng/ml) or CpG DNA (20 µg/ml) was 0-min time point; KB (200 µM) was separately added at 40 min and 20 min before the 0-min time point, and 0, 20, 40, 60 and 120 min after the 0-h time point; cells continued to be cultured for 12 h; then the supernatant was collected; the concentration of TNF-α was detected according to the manufacturer's instructions of ELISA kit; result was expressed by means of mean ± standard deviation.
  3. (3) Cells stimulation under serum-free conditions: RAW 264.7 culture medium was replaced with serum-free DMEM; KB (50, 100 and 200 µM) and LPS (100 ng/ml) or CpG DNA (10 µg/ml) were added at the meantime; cells were continued to be cultured for 12 h; then the supernatant was collected; the concentration of TNF-α was detected according to the manufacturer's instructions of ELISA kit; result was expressed by means of mean ± standard deviation.

18.2: Results:



[0078] When LPS or CpG DNA was loaded after preincubation with PBS or KB for 20 min or 40 min, the inhibition of KB on TNF-α release induced by LPS and CpG DNA was significantly enhanced. And then, when the time point of adding LPS (200 ng/ml) or CpG DNA (20 µg/ml) was 0-min time point, and KB (200 µM) was separately added at 40 min and 20 min before the 0-min time point, and 0, 20, 40, 60 and 120 min after the 0-h time point, the results show that, there was no significant difference between the group in which KB was added before the stimulations of LPS and CpG DNA and the group in which KB was added at the mean time of the stimulations of LPS and CpG DNA; when KB was added at 60 min after stimulation, there are still inhibition on TNF-α release induced by LPS and CpG DNA; when KB was added more than 120 min after stimulation, it would no longer have inhibitory activity on TNF-α release. In addition, under serum-free conditions, KB can still inhibit the release of TNF-α in RAW264.7 cells induced by LPS and CpG DNA in a dose-dependant manner, which eliminated the possibility that KB play an indirect role in inhibition on LPS and CpG DNA by acting on the serum protein. The results were shown in Figure 22. Wherein Figure 22a shows the inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA, in which KB was loaded after preincubation with LPS or CpG DNA; Figure 22b shows the inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA, in which KB was loaded at various time points; Figure 22c shows the inhibition of KB on TNF-α release in RAW264.7 cells induced by LPS and CpG DNA, in which KB was loaded without serum.

Embodiment 19: Detection of inhibitory activity of KB on release of TNF-α and IL-6 in RAW264.7 cells induced by various pathogen-associated molecular patterns


19.1 Methods:



[0079] RAW264.7 cells were stimulated by six pathogen-associated molecular patterns, LPS (100 ng/ml), CpG DNA (CpG, 10 µg/ml), Pam3CSK4 (Pam3, 10 µg/ml), Poly I:C (I:C, 20 µg/ml), TNF-α (50 ng/ml) and IL-1β (50 ng/ml), and added with KB (final concentration of 200 µM) in the meantime. According to the method in embodiment 6, the supernatant was collected. The concentration of TNF-α was detected according to the manufacturer's instructions of ELISA kit. Result was expressed by means of mean ± standard deviation.

19.2 Results:



[0080] KB (200 µM) intervention can only inhibit the release of TNF-α and IL-6 induced by LPS and CpG DNA, but has no antagonistic effect on other irritant. The result showed that KB effect only targets at LPS and CpG DNA. The result was shown in Figure 23. Wherein Figure 23a shows the inhibition of KB on TNF-α release in RAW264.7 cells induced by various pathogen-associated molecular patterns, and Figure 23b shows the inhibition of KB on IL-6 release in RAW264.7 cells induced by various pathogen-associated molecular patterns.

Embodiment 20: Flow cytometry detection of KB influence on the binding of LPS and CpG DNA (CPG) with RAW264.7 cells


20.1 Methods:



[0081] RAW264.7 cells was diluted to 1×106/ml in DMEM supplemented with 10% (v/v) NCS; 2 ml of the above suspension was added into 24-well cell culture plates and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h; for the purpose of experiment three groups were established: medium group, stimulation group and KB treatment group; no reagent was added into medium group; stimulation group was added with FITC-LPS (200 ng/ml) and 5-FAM-CpG DNA (10 µg/ml); KB treatment group was added with KB (final concentrations of 50, 100 and 200 µM) in the meantime of adding LPS and CpG DNA; cells continued to be cultured for 30 min, washed thrice with PBS, and stored in dark place until the fluorescence intensity of cell membrane surfaces was detected by flow cytometry.

20.2 Result:



[0082] With untreated RAW264.7 cells served as a negative contol, the curve moved toward right after cells were treated with FITC-LPS and 5-FAM-CpG DNA; by plotting according to mean fluorescence intensity (MFI) of cell membrane, MFI was significantly increased after cell were treated with FITC-LPS and 5-FAM-CpG DNA, which suggested that LPS and CpG DNA had been binded with cell membrane receptor; while FITC-LPS and 5-FAM-CpG DNA was added, intervention by various concentration of KB can decrease the MFI of cell membrane in a dose-dependent manner, and inhibited the right shift of curve, which has statistical significance. The results were shown in Figure 24. Wherein Figure 24a shows the influence of KB on mean fluorescence intensity of LPS on RAW264.7 cell surface, and Figure 24b shows the influence of KB on mean fluorescence intensity of CpG DNA on RAW264.7 cell surface.

Embodiment 21: Observation of KB influences on binding and cellular internalization of LPS and CpG DNA (CPG) to RAW264.7 cells under a confocal microscopy


21.1 Methods:



[0083] RAW264.7 cells were cultured in 20 mm cell culture dishes for confocal microscopy applications, and diluted to 5×105/ml in DMEM supplemented with 10% (v/v) NCS; 1 ml of the above suspension was transferred into each cell culture dishes and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h; for the puepose of experiment three groups were established, medium group, stimulation group and KB treatment group; the concentration and loading patterns of each group were consistent with Embodiment 12; the cells were then fixed with 4% paraform for 10 min after 30 min of culture, and washed thrice with PBS; nucleus were stained with DAPI (100 ng-mL-1) for 2 min, washed with PBS thrice, mounted with a solution of 50% glycerol and 50% PBS, and stored in dark place until intensity and distribution of fluorescence of LPS and CpG DNA on RAW 264.7 cells surface were observed under a confocal microscopy.

21.2 Results:



[0084] Green fluorescence of FITC or 5-FAM can not be observed on the untreated RAW264.7 cells surface, and only the blue fluorescence of DAPI stain was observed. After FITC-LPS (200 ng/ml) or 5-FAM-CpG DNA (10 µg/ml) was added, the punctate distribution of fluorescence on the surface of and inside RAW264.7 cells significantly increased, which suggested that LPS or CpG DNA were binded to cell membrane receptor and internalized into the cells. After intervention with 50, 100 and 200 µM KB, the green fluorescence intensity of FITC or 5-FAM on the surface of and inside RAW264.7 cells was significantly weakened, and the inhibitory effect of KB showed obvious dose-dependent. The results were shown in Figure 25. Wherein Figure 25a shows the KB influence on binding and cellular internalization of LPS to RAW264.7 cells, and Figure 25b shows the KB influence on mean fluorescence intensity of 5-FAM-CpG DNA on RAW264.7 cell surface.

Embodiment 22: Assay of KB inhibition on the up-regulated expression of TLR4 and TLR9 induced by LPS and CpG DNA


22.1 Methods:



[0085] The dose of KB, LPS and CpG DNA, specific steps, and the calculation and expression of results in the assay of expression of TLR4 and TLR9 were all consistent with methods of embodiment 15. Wherein the primer sequences of TLR4 and TLR9 are as follows:
 Sequences
Mouse TLR4 Upstream primer: 5'- AAGGCATGGCATGGCTTACAC-3'
  Downstream primer: 5'-GGCCAATTTTGTCTCCACAGC-3'
Mouse TLR9 Upstream primer: 5'-TCGCTCAACAAGTACACGC-3'
  Downstream primer: 5'-GCTCTGCATCATCTGCCTC-3'
Mouse β-actin Upstream primer: 5'-GGGAAATCGTGCGTGACATCAAAG-3'
  Downstream primer: 5'-CATACCCAAGAAGGAAGGC TGGAA-3'

22.2 Result:



[0086] Results of RT-PCR assay show that with the expressions of TLR4 and TLR9 in untreated RAW264.7 cells serving as a control, stimulation of LPS and CpG DNA can significantly up regulated the expression of TLR4 and TLR9; after intervention with 100 and 200 µM KB, the up-regulated expression of TLR4 and TLR9 was significantly inhibited, which suggested that KB can block the up-regulated expression of TLR4 and TLR9, and then inhibited further stimulation. The results were shown in Figure 26. Wherein Figure 26a shows the inhibition of KB on the up-regulated expression of TLR4 mRNA induced by LPS and CpG DNA, and Figure 26b shows the inhibition of KB on the up-regulated expression of TLR9 mRNA induced by LPS and CpG DNA.

Embodiment 23: Inhibition of KB on up-regulated phosphorylation of signaling molecules of IκB-α and p38 in RAW264.7 cells stimulated by LPS, CpG DNA, TNF-α and IL-1β


23.1 Methods:



[0087] Extraction of cytoplasmic protein: RAW264.7 cells were diluted to 1×106/ml in DMEM supplemented with 10% (v/v) NCS; 5 ml of the above suspension was transferred into cell culture bottles and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h; a preliminary experiment was first performed, in which RAW264.7 cells were stimulated by LPS (100 ng/ml), CpG DNA (10 µg/ml), TNF-α (50 ng/ml) or IL-1β (50 ng/ml) for 15, 30, 45 and 60 min respectively; for the purpose of formal experiment a medium group, a KB control group, stimulation group (LPS, CpG DNA, TNF-α or IL-1β) and a KB treatment group (LPS+KB group, CpG DNA+KB group, TNF-α+KB group and IL-1β+KB group) were established; no reagent was added in medium group; KB control group was only added with KB (200 µM); stimulation group was added with LPS (100 ng/ml), CpG DNA (10 µg/ml), TNF-α (50 ng/ml) or IL-1β (50 ng/ml); KB treatment group was added with KB (100, 200 µM) in the meantime of adding LPS, CpG DNA, TNF-α or IL-1β; the duration time of cell culture was based on the preliminary experiment (30 min); cells were washed with PBS and centrifuged to collect cells; supernatant was sucked and discarded; the cell pellet was collected for further experiment; each 20 µl cell pellet was added with 200 µl cytoplasm protein extraction reagents supplemented with PMSF, shook vigorously for 5 seconds to completely suspend and disperse the cell pellet, chilled for 10 to 15 min in an ice bath, centrifuged at 12,000 g at 4°C for 5 min; the supernatant was instantly transferred into a precooled plastic tube, which was the cytoplasmic protein obtained by extraction;

[0088] SDS-PAGE gel electrophoresis:
① Separating gel and stacking gel were prepared as follows:
10% separating gel (5.0 ml) 5% stacking gel (2.0 ml) 
Distilled water 1.3 ml Distilled water 1.4 ml
30%Acr-Bis(29:1) 1.7 ml 30%Acr-Bis(29:1) 0.33 ml
1M Tris-HCl(pH 8.8) 1.9 ml 1 M Tris-HCl (pH 6.8) 0.25 ml
10% SDS 0.05 ml 10% SDS 0.02 ml
10% AP 0.05 ml 10% AP 0.02 ml
TEMED 0.002 ml TEMED 0.002 ml

② Gel casting: Separating gel was cast to approximately 1.5 cm from the top of the upper panel; after separating gel was cast, dd H2O was added into it until overflow; gel was kept horizontally at room temperature for 30 min; the dd H2O was discarded and blotted up with filter paper after gelling; stacking gel was cast to the top of the upper panel; a 10-well gel comb was inserted vertically into the gel, and pulled out gently and vertically after 30 min; gel wells were washed twice with dd H2O to remove remanent gel;
③ Sample preparation: Protein sample was mixed with 5× concentrated loading buffer in proportion of 4: 1, and denatured at 100 °C for 5 min;
④ Prerunning: Gels were run at 120 V for 5 min with zero-load to remove the foreign substance in gel;
⑤ Loading: Sample loading volume was adjusted according to protein concentration to ensure 20 µg protein content of each sample; samples were loaded with microsyringe (5 µl protein molecular weight marker were loaded);
⑥ Electrophoresis: Gels were run at 80 V for 30 min (stacking), then 100 V for 60 min (separating), and then terminated when bromophenol blue indicator had reached 1 cm from the bottem of panel;

[0089] Membrane transfer: Wet transfer method was adopted, under the conditions of 200 mA, 60 min;

Block and hybridization:



[0090] 

① Membrane was took out from electrophoretic transfer, washed with 0.05% PBST, and blocked at 200 rpm on a horizontal shaker for 1 h;

② Primary antibody concentrate was diluted with blocking buffer in proportion of 1:1000; the protein bands were placed on wax-plate; antibody was dropwise added until bands were completely covered, and incubated overnight at 4°C;

③ Bands were washed 5 times with PBST on a horizontal shaker at 200 rpm for 5 min each time;

④ Type of Enzyme labeled secondary antibody were defined according to resourse of the primary antibody; secondary antibody was diluted in proportion of 1:5000, added into culture dishes, and incubated at 37°C for 30 min;

⑤ Bands were washed 5 times with PBST on a horizontal shaker at 200 rpm for 5 min each time;


Identification of chemiluminescence: Equal volume of chemiluminescent substrates A and B were mixed to make working solution, which was dropwise added onto the membrane; the detection was performed by gel documentation systems using chemiluminescence, and the images were collected and saved;


23.2 Results:



[0091] After LPS and CpG DNA were bound to receptors, intracellular signal transduction pathways were started, and signaling molecules related to inflammatory response were activated. Phosphorylated and total protein of IκB-α and p38 were detected using western blot. The detection results of p38 show that: the expression levels of p38 and tubulin internal reference in each group were basically in agreement; there were hardly any p-p38 expression in medium group and KB control group; p-p38 expression in LPS stimulation group and CpG stimulation DNA group was significantly up regulated; after intervention by KB (100 and 200 µM), p-p38 expression was significantly inhibited. The detection results of IκB-α show that: the expression levels of p38 and tubulin internal reference in each group were basically in agreement; with medium group serving as a control, addition of KB alone had no influence on the expression of IκB-α and p-IκB-α; stimulation of LPS and CpG DNA lead to the degradation of IκB-α (the degradation of IκB-α can not be detected after RAW264.7 cells were stimulated by LPS and CpG DNA for more than 45 min, therefore the stimulation time in formal experiment was chosen as 30 min) and the up-regulated expression of p-IκB-α; after intervention by KB at the same concentration, the degradation of IκB-α and the up-regulated expression of p-IκB-α both were significantly inhibited, which suggested that KB can neutralized LPS and CpG DNA and inhibited the activation of intracellular signaling molecules induced by them. The results were shown in Figure 27. Wherein Figure 27a shows the degradation of IκB-α in RAW264.7 cells after stimulated by LPS, CpG DNA, TNF-α and IL-1β for different time (15, 30, 45, and 60 mins), and Figure 27b shows the inhibition of KB on up-regulated phosphorylation of signaling molecules p38 induced by LPS, CpG DNA, TNF-α and IL-1β, and the inhibition of KB on degradation and phosphorylation of IκB-α, in RAW264.7 cells.

Embodiment 24: Inhibition of KB on NF-κB activation in RAW264.7 cells induced by LPS and CpG DNA


24.1 Methods:



[0092] 
  1. (1) Extraction of nuclear protein: RAW264.7 cells was adjusted to 1×106/ml in DMEM supplemented with 10% (v/v) NCS; 5 ml of the above suspension was transferred into cell culture bottles and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h; for the purpose of experiment a medium group, a KB control group, a stimulation group (LPS or CpG DNA) and KB treatment group (LPS+KB group, CpG DNA+KB group) were established; no reagent was added in medium group; KB control group only added with KB (200 µM); stimulation group was added with LPS (100 ng/ml) or CpG DNA (10 µg/ml); KB treatment group was added with KB (100, 200 µM) in the meantime of adding LPS or CpG DNA; cells continued to be cultured for 2 h, then washed with PBS and centrifuged to collect cells; supernatant was sucked and discarded; the cell pellet was collected for further experiment; each 20 µl cell pellet was added with 200 µl cytoplasm protein extraction reagents A supplemented with PMSF, shook vigorously for 5 seconds to completely suspend and disperse the cell pellet, and chilled for 10 to 15 min in an ice bath; the suspension was added with 10 µl cytoplasm protein extraction reagents, shook vigorously for 5 seconds, chilled for 1 min in an ice bath, then shook vigorously for 5 seconds, and centrifuged at 12,000-16,000 g at 4°C for 5 min; supernatant was sucked and discarded; the cell pellet was added with 50 µl cytoplasm protein extraction reagents supplemented with PMSF, shook vigorously for 20 seconds to completely suspend and disperse the cell pellet, then put in an ice bath, shook vigorously for 20 seconds every 1-2 min for approximately 30 min, and centrifuged at 12,000 g at 4°C for 10 min; the supernatant was transferred into a precooled EP tube, which was the cytoplasmic protein obtained by extraction, and then stored at -70°C for further detection;
    Detection of NF-κB activations using ELISA: Each well was added with 30 µl binding solution (3.2 µl DTT and 16.2µl Herring sperm DNA were diluted in 1.6 ml binding solutions); each sample well was added with 20 µl sample (contain 10 µg cytoplasmic protein obtained by extraction); positive control wells was added with 20 µl p50; blank control wells were added with 20 µl dissolution buffer (0.9 µl 1M DTT and 1.8µl protease inhibitors was diluted in 177.3 µl dissolution buffer AM2); the microtiter plate was shaken for 30 seconds for completely mixing, incubated at room temperature for 1 h, and then washed thrice with 200 µl 1×wash solution (450 µl 10×wash solution were diluted in 4.05 ml ddH2O) and gentle shaking for 5 min each time; each well was added with 100 µl NF-κB antibody (1:1000), incubated for 1 h, then washed thrice with 200 µl 1×wash solution and gentle shaking for 5 min each time; each well was added with 100 µl HRP antibody (1:1000), incubated for 1 h, then washed four times with 200 µl 1×wash solution and gentle shaken for 5 min each time; each well was added with 100 µl detection reagent, incubated for 5 min away from light, and then added with 100 µl stop solution; the absorbance value at 450 nm of each well was detected.
  2. (2) Luciferase reporter gene assay: RAW 264.7 cells were co-transfected with plasmid pGL-luc2P/NF-κBRE and pGL-hRluc according to the manufacturer's instructions of Invitrogen Lipofectamine 2000 reagent. RAW264.7 cells were stimulated by LPS (100 ng/ml) or CpG DNA (10 µg/ml) 48 h after transfection, and intervened by KB (200 µM) simultaneously. After incubation for 6 h, detection was performed according to the manufacturer's instructions of Dual-Glo Luciferase assay kit.

24.2 Result:



[0093] Transcription factors such as NF-κB were activated by activation of signaling molecules induced by LPS and CpG DNA. P50 and p65, the subunit of NF-κB in nuclear proteins, were detected using ELISA. The results show that: As compared with the unstimulated RAW264.7 cells, KB alone has no influence on the expression of p50 and p65; the stimulation of LPS and CpG DNA can lead to a significant increase of p50 and p65 levels; after intervention of 200 µM KB, the increase of p50 and p65 levels in nuclear proteins was significantly inhibited. Results of luciferase reporter gene assay also show that KB can inhibit NF-κB activation in RAW264.7 cells induced by LPS and CpG DNA. The results were shown in Figure 28. Wherein Figure 28a shows the inhibition of KB on up-regulation of NF-κB p50 subunit in RAW264.7 cell nucleus induced by LPS and CpG DNA; Figure 28b shows the inhibition of KB on up-regulation of NF-κB p65 subunit in RAW264.7 cell nucleus induced by LPS and CpG DNA; and Figure 28c shows assay of KB inhibition on NF-κB activation in RAW264.7 cells induced by LPS and CpG DNA using a luciferase reporter gene assay.

Embodiment 25: Inhibition of KB on up-regulated expression of TLR4, TLR9, MyD88 and NF-κB (p65) in RAW264.7 cells stimulated by LPS and CpG DNA


25.1 Methods:



[0094] 
(1) KB inhibition on up-regulated mRNA expression of TLR4, TLR9, MyD88 and NF-κB p65) in RAW264.7 cells stimulated by LPS and CpG DNA (Semi-Quantitative RT-PCR): RAW264.7 cells was adjusted to 1×106/ml in DMEM supplemented with 10% (v/v) NCS; for the purpose of experiment a LPS or CpG DNA stimulation group, a KB treatment group and a medium group were established; LPS or CpG DNA stimulation group was separately added with LPS (100 ng/ml) or CpG DNA (10 µg/ml); KB treatment group was added with KB (200 µM) in the meantime of adding LPS (100 ng/ml) or CpG DNA (10 µg/ml); no reagent was added in medium group; cells continued to be cultured for 4 h after sample loading; total RNA extraction and reverse transcription were performed according to the procedure of embodiment 15; mRNA of TLR4, TLR9 and MyD88 were amplified by PCR; relevant primer sequences are as follows:
 Sequences
Mouse TLR4 Upstream primer: 5'- AAGGCATGGCATGGCTTACAC-3'
  Downstream primer: 5'-GGCCAATTTTGTCTCCACAGC-3'
Mouse TLR9 Upstream primer: 5'-TCGCTCAACAAGTACACGC-3'
  Downstream primer: 5'-GCTCTGCATCATCTGCCTC-3'
Mouse MyD88 Upstream primer: 5'-ACTCGCAGTTTGTTGGATG-3'
  Downstream primer: 5'-CACCTGTAAAGGCTTCTCG-3'
Mouse GAPDH Upstream primer: 5'-CTGCACCACCAACTGCTTAG-3'
  Downstream primer: 5'-GTCTGGGATGGAAATTGTGA-3'


[0095] Reaction mixtures were added into 0.2 ml PCR tubes. The reaction mixture included 1 µl cDNA, 10.0 µl 2×Taq Master Mix, 1 µl upstream primer (10µM), 1 µl downstream primer (10 µM) and 7 µl RNase-free H2O. PCR programs are as follows:
StepsTemperatureTimesCycles
Initial denaturation 94°C 3 min  
Denaturation 94°C 30 sec  
Annealing 58°C 30 sec 26
Extension 72°C 1 min  
Final extension 72°C 7 min  
Preservation 4°C    


[0096] Finally, the PCR products were detected by agarose gel electrophoresis; 1% agarose gel was prepared and cast; 5µl PCR products of each tube were loaded, electrophoresed at 100 v for 30 min; then gel was took out and scanned; the images were analysed by Quantity One software.

(2) Inhibition of KB on activation of NF-κB p65 in RAW264.7 cells induced by LPS and CpG DNA: Methods are as above; nucleoprotein extraction continued to be incubated for 1 h after sample loading; then, NF-κB p65 in it was assayed using westernblot; the procedure of nucleoprotein extraction and westernblot were consistent with embodiment 23.



[0097] 25.2 Results: (1) Assay of semi-quantitative RT-PCR shows that KB (200 µM) can inhibited up-regulated expression of TLR4, TLR9 and MyD88 in RAW264.7 cells stimulated by LPS and CpG DNA. Results were shown in Figure 29a and 29b. Wherein Figure 29a shows the inhibition of KB on up-regulated expression of TLR4 and TLR9 mRNA in RAW264.7 cells induced by LPS and CpG DNA, and Figure 29b shows the inhibition of KB on up-regulated expression of MyD88 mRNA in RAW264.7 cells induced by LPS and CpG DNA; (2) Results of western blot show that KB (200 µM) can inhibit the up-regulation of NF-κB p65 in RAW264.7 cell nucleus induced by LPS (100 ng/ml) and CpG DNA (10 µg/ml), which suggests that KB can inhibit the activation of NF-κB in RAW264.7 cells induced by stimulation of LPS and CpG DNA. The results were shown in Figure 29c.

Embodiment 26: Influence of the combination of KB with LPS or CpG DNA on vitality of RAW264.7 cells and murine peritoneal macrophages (MTT method)


26.1 Methods:



[0098] 
  1. (1) Influence on vitality of RAW264.7 cells: According to embodiment 7, for the pupose of experiment a medium group, KB group (25, 50, 100, 200, 400 and 800 µM), a LPS (100 ng/ml) + KB (0, 100, 200 and 400 µM) group and a CpG DNA (10 µg/ml) + KB (0, 100, 200 and 400 µM) group were established; MTT was dissolved with PBS to make 5 mg/ml solution and filtered, which served as stock solution and stored at -20°C for further detection; RAW264.7 cells were adjusted to 1×106/ml in DMEM medium, added into 96-well plates (200 µl per well), and cultured at 37 °C in a 5% CO2 humidified incubator for 4 h; the specified concentration of LPS, CpG DNA and KB were separately loaded according to the grouping; cells were cultured at 37 °C in a 5% CO2 humidified incubator for 24 h, centrifuged at 1000 rpm/min for 5 min; the supernatant was sucked and discarded; each well was added with 180 µl cell culture medium and 20 µl MTT stock solution, then cultured at 37 °C in a 5% CO2 humidified incubator for 4 h, and centrifuged at 1000 rpm/min for 10 min; then the supernatant was sucked and discarded; each well was added with 150 µl DMSO, and shook for 10 min for the dissolution of the crystals; RAW264.7 cells vitality was expressed as absorbance values at 550 nm of each well, which were instantly assayed by ELIASA.
  2. (2) Influence on vitality of murine peritoneal macrophages: Experiment methods are as above. Influences of the combination of KB with LPS or CpG DNA on vitality of murine peritoneal macrophages were assayed.

26.2 Result:



[0099] After RAW264.7 cells were treated with KB or KB plus LPS or CpG DNA, there was no statistic difference on absorbance values between medium group and other groups, which suggests that the inhibition of KB on release of TNF-α and IL-6 in RAW264.7 cells was not caused by its cytotoxicity. The same result was also obtained from observation on the vitality of murine peritoneal macrophages, which suggested that KB antagonism on LPS and CpG DNA in primary cell was not induced by influence on vitality of murine peritoneal macrophages. The results were shown in Figure 30. Wherein Figure 30a shows the influence of KB on vitality of RAW264.7 cells; Figure 30b shows the influence of the combination of KB with LPS or CpG DNA on vitality of RAW264.7 cells; Figure 30c shows the influence of KB on vitality of murine peritoneal macrophages; and Figure 30d shows the influence of the combination of KB with LPS or CpG DNA on vitality of murine peritoneal macrophages.

Embodiment 27: Observation of KB protection (dose-dependent relationship) on mice challenged by lethal dose of heat-killed Escherichia coli


27.1 Methods:



[0100] 
  1. (1) Single dose experiment:

    ① Experiment 1: A total of 40 Kunming mice (18-20 g), half male and half female, were divided into two groups randomly, heat-killed E. coli control group and KB (30 mg/kg) treatment group; each group has 20 mice; after animal weighing, heat-killed E. coli group was injected with heat-killed Escherichia coli (200 µl per 20 g body weight) and sterile saline (200 µl per 20 g body weight); KB treatment group was injected with KB (200 µl per 20 g body weight) at 5 min after heat-killed E. coli was injected; the injection doses of heat-killed E. coli were 1.0×1011 CFU/kg, and injection doses of KB were 30 mg/kg. After injection, mice in each group were housed separately and feed with sufficient and equivalent food and water.The general status (mental status, appetite, activity and response to stimuli), mortality rate and time of death, of mice in each group, were observed in 7 days after injection.

    ② Experiment 2: KB was diluted to 1.5, 3.0 and 6.0 mg/ml with sterile saline, and heat-killed E. coli suspension was diluted to 1.0×1010 CFU/ml with sterile saline for further detection; a total of 80 Kunming mice, half male and half female, were randomly divided into heat-killed E. coli control group, KB 15 mg/kg treatment group, KB 30 mg/kg treatment group and KB 60 mg/kg treatment group; each group has 16 mice; after animal weighing, heat-killed E. coli group was injected with heat-killed Escherichia coli (200 µl per 20 g body weight) and sterile saline (200 µl per 20 g body weight); KB treatment groups were injected with KB (200 µl per 20 g body weight) at concentrations of 1.5, 3.0 and 6.0 mg/ml respectively at 5 min after heat-killed E. coli injection. After injection, mice in each group were housed separately and feed with sufficient and equivalent food and water.The general status (mental status, appetite, activity and response to stimuli), mortality rate and time of death, of mice in each group, were observed in 7 days after injection.

  2. (2) Multiple dose experiment: KB was diluted to 0.125, 0.25 and 0.5 mg/ml with sterile saline, and heat-killed E. coli suspension was diluted same as above. Experiment grouping was the same as above. The KB injection doses were 1.25, 2.5 and 5 mg/kg, and were administrated every 8 h for 3 days. The general status, mortality rate and time of death, of mice in each group, were observed in 7 days after injection.

27.2 Result:



[0101] 
  1. (1) Single dose experiment: After heat-killed Escherichia coli injection, KM mice,gathered and shivered, do not drink and eat. The symptoms became worse 6 h after injection. Their reactivity to external stimuli greatly decreased, and body temperature dropped. Death began to occur in severe cases, and peaked at 12-24 h. After 24 h, only a few individual death occurred, and there were no additional deaths after 72 h. The mortality rate in 7 days decreased with the increasing doses of KB. The results were shown in Figure 31 a and 31 b. Wherein Figure 31 a shows the protection of KB (30 mg/kg) on mice challenged by lethal dose of heat-killed Escherichia coli. , and Figure 31b shows the protection of KB (15, 30 and 60 mg/kg) on mice challenged by lethal dose of heat-killed Escherichia coli.;
  2. (2) Multiple dose experiment: In multiple dose experiment (administration every 8 h for 3 days), results also show that KB can improve survival rates in model animal. The results were shown in Figure 31c.

Embodiment 28: Observation on therapeutic effect of KB on mice challenged by sublethal dose of heat-killed Escherichia coli


28.1 Methods:



[0102] Kunming mice were randomly divided into two groups, and there were 56 mice in each group; heat-killed E. coli was diluted to make 1.0×109 CFU/ml suspension, and KB was dissolved to 6 mg/ml with sterile saline; caudal vein injection was adoped; medium group was injected with heat-killed Escherichia coli (0.2 ml per 20 g body weight) and sterile saline (0.2 ml per 20 g body weight); KB treatment groups were injected with heat-killed E. coli suspension S (0.2 ml per 20 g body weight) and KB (0.2 ml per 20 g body weight). Orbital venous blood of mice in medium group and KB treatment group was collected at time point of 0, 4, 8, 12, 24, 48 and 72h after injection, the specific methods are: mice were killed by cervical dislocation, and immersed in 75% ethanol for skin degerming; the eye of mouse was removed, and blood was collected into a 1.5 ml EP tube; 10 µl blood were added into 190 µl nonpyrogenic water; solution was kept standing for 5-10 min for nutural sedimentation, and centrifuged at 1000 rpm for 10 min; the supernatant was transferred into a new centrifuge tube and stored at -204°C for further detection; the rest was keep standing until aggregation and serum precipitation, then centrifuged at 3000 rpm for 10 min; the supernatant was transferred into a new centrifuge tube and stored at -20°C for further detection;
  1. (1) Detection of LPS levels in plasma: 10 µl plasma sample was dissolved in 190 µl sterile saline and mixed. Detection of LPS levels was performed according to the operating procedure of EDS-99 Bacterial Endotoxin Detecting system. Result was expressed by means of mean ± standard deviation.
  2. (2) Detection of serum cytokine levels: Because of the small blood volume of mouse, serum was diluted 2 times for detection. Dectection of the TNF-α concentration was performed according to the manufacturer's instructions of ELISA kit. Result was expressed by means of mean ± standard deviation.

28.2 Result:



[0103] LPS levels in normal KM mice plasma were below the detection limit (less than 0.0015 EU/ml); after injection of sublethal dose of heat-killed E. coli (1.0×1010 CFU/ml), LPS levels in KM mice plasma increased rapidly, peaked at 8 h (819.42±159.02 EU/ml), then decreased gradually and close to normal levels at 72 h; the change tendency of LPS levels in mice plasma in KB treatment group were consistent with heat-killed E.coli control group in this period, and LPS levels in mice plasma in KB treatment group were significantly lower (p<0.05 or p<0.01) than heat-killed E.coli control group in time point of 4, 8, 12, 24 and 48 h; there were only basic levels of TNF-α exist in normal KM mice serum (less than 100 pg/ml); after injection of sublethal dose of heat-killed E. coli (1.0×1010 CFU/ml), LPS levels in KM mice serum increased rapidly, peaked at 4 h (4068.40±962.49 pg/ml), then decreased gradually and close to normal levels at 72 h; the change tendency of TNF-α levels in mice serum in KB treatment group were consistent with heat-killed E.coli control group in this period, and TNF-α levels in mice serum in KB treatment group were significantly lower (p<0.01) than heat-killed E.coli control group in time point of 4, 8, 12 and 24 h. The results were shown in Figure 32. Wherein Figure 32a shows the influence of KB on LPS levels in plasma of mice challenged by sublethal dose of heat-killed Escherichia coli., and Figure 32b shows the influence of KB on TNF-α levels in serum of mice challenged by sublethal dose of heat-killed Escherichia coli.

Embodiment 29: Observation of KB protection (time-dependent relationship) on mice challenged by lethal dose of heat-killed Escherichia coli.


29.1 Methods:



[0104] KB was diluted to 6.0 mg/ml with sterile saline, and heat-killed E. coli suspension was diluted to 1.0×1010 CFU/ml with sterile saline for further detection; a total of 96 Kunming mice, half male and half female, were randomly divided into heat-killed E. coli control group, 0 h KB treatment group, 2 h KB treatment group, 4 h KB treatment group, 6 h KB treatment group and 8 h KB treatment group; each group has 16 mice; after animal weighing, heat-killed E. coli group was injected with heat-killed Escherichia coli (200 µl per 20 g body weight) and sterile saline (200 µl per 20 g body weight); KB treatment groups were respectively injected with KB (200 µl per 20 g body weight) at time point of 0, 2, 4, 6 and 8 h after heat-killed E. coli injection. After injection, mice in each group were housed separately and feed with sufficient and equivalent food and water.The general status (mental status, appetite, activity and response to stimuli), mortality rate and time of death, of mice in each group, were observed in 7 days after injection.

29.2 Results:



[0105] Intervention by single dose of KB (60 mg/kg) at 2 h after heat-killed E. coli injection (1.0×1011 CFU/kg) still can increase the survival rate of model animal. But treatment after 2 h (4, 6 and 8 h) no longer has a significant protective effect. The results were shown in Figure 33.

Embodiment 30: Influence of KB on major organ pathological morphous of mice


30.1 Methods:



[0106] A total of 16 Kunming mice were randomly divided into four groups; each group has 4 mice, half male and half female; for the purpose of experiment a medium group and a KB (60 mg/kg) treatment group were established; mice in medium group were immediately killed by cervical dislocation, and KB treatment group were killed separately killed at 24, 48 and 72 h after injection; the cavitas thoracis and abdominal cavity of mice were cut open; organs such as heart, liver, lung, kidney and intestine were moved out, rinsed with sterile saline, plunged into 10% formaldehyde solution for fixing, dehydrated, embedded in paraffin, HE dyed and mounted; organ histopathological changes were observed under a light microscope.

30.2 Result:



[0107] As compared with the medium group, in mouse lung of the KB treatment group there were no congestion and inflammatory cell infiltration; in mouse liver of KB the treatment group, liver cell surrounded central veins had a clear structure, and there were no pathological changes such as cellular swelling and necrosis; in mouse kidney of the KB treatment group, glomeruli and bowman's capsule in each time point had normal morphology and no obvious changes; in mouse cardiac muscle of the KB treatment group, myocardial cells arranged in clear rules and there were no cell necrosis and inflammatory cell infiltration; the above results show that morphous of heart, lung, liver and kidney in mice of the KB treatment group in each time point (24, 48 and 72 h) had no obvious changes under light microscope, which suggests that there were no significant changes in major organs of mice after single dose injection of KB (60mg/kg). The results were shown in Figure 34. Wherein Figure 34a shows the lung morphology of mice after KB injection; Figure 34b shows the liver morphology of mice after KB injection; Figure 34c shows the kidney morphology of mice after KB injection; Figure 34d shows the cardiac muscle morphology of mice after KB injection.

SEQUENCE LISTING



[0108] 

<110> THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERITY OF PLA
<120> Use of Kukoamine A and Kukoamine B
<130>
<160> 24
<170> PATENTIN VERSION 3.3

<210> 1
<211> 24
<212> DNA
<213> Upstream primer for PCR amplification of mouse TNF-α mRNA
<400> 1
caggttctgt ccctttcact cact

<210> 2
<211> 24
<212> DNA
<213> Downstream primer for PCR amplification of mouse TNF-α mRNA
<400> 2
gttcagtaga cagaagagcg tggt

<210> 3
<211> 24
<212> DNA
<213> Upstream primer for PCR amplification of mouse IL-6 mRNA
<400> 3
tggagtacca tagctacctg gagt

<211> 24
<212> DNA
<213> Downstream primer for PCR amplification of mouse IL-6 mRNA
<400> 4
tccttagcca ctccttctgt gact

<210> 5
<211> 18
<212> DNA
<213> Upstream primer for PCR amplification of mosue iNOS mRNA
<400> 5
tcctacacca caccaaac

<210> 6
<211> 19
<212> DNA
<213> Downstream primer for PCR amplification of mouse iNOS mRNA
<400> 6
ctccaatctc tgcctctcc

<210> 7
<211> 20
<212> DNA
<213> Upstream primer for PCR amplification of mouse COX-2 mRNA
<400> 7
tagcagatga ctgcccaact

<210> 8
<211> 20
<212> DNA
<213> Downstream primer for PCR amplification of mosue COX-2 mRNA
<400> 8
cacctctcca ccaatgacct

<210> 9
<211> 24
<212> DNA
<213> Upstream primer for PCR amplification of mouse β-actin mRNA
<400> 9
gggaaatcgt gcgtgacatc aaag

<210> 10
<211> 20
<212> DNA
<213> Downstream primer for PCR amplification of mouse β-actin mRNA
<400> 9
catacccaag aaggaaggct ggaa

<210> 11
<211> 21
<212> DNA
<213> Upstream primer for PCR amplfication of mouse TLR4 mRNA
<400> 11
aaggcatggc atggcttaca c

<210> 12
<211> 21
<212> DNA
<213> Downstream primer for PCR amplification of mouse TLR4 mRNA
<400> 12
ggccaatttt gtctccacag c

<210> 13
<211> 19
<212> DNA
<213> Upstream primer for PCR amplification of mouse TLR9 mRNA
<400> 13
tcgctcaaca agtacacgc

<210> 24
<211> 19
<212> DNA
<213> Downstream primer for PCR amplification of mouse TLR9 mRNA
<400> 14
gctctgcatc atctgcctc

<210 15
<211> 24
<212> DNA
<213> Upstream primer for PRC amplification of mouse β-actin mRNA
<400> 15
gggaaatcgt gcgtgacatc aaag

<210> 16
<211> 24
<212> DNA
<213> Downstream primer for PCR amplification of mouse β-actin mRNA
<400> 16
catacccaag aaggaaggct ggaa

<210> 17
<211> 21
<212> DNA
<213> Upstream primer for PCR amplification of mouse TLR4 mRNA
<400> 17
aaggcatggc atggcttaca c

<210> 18
<211> 21
<212> DNA
<213> Downstream primer for PCR amplification of mouse TLR4 mRNA
<400> 18
ggccaatttt gtctccacag c

<210> 19
<211> 19
<212> DNA
<213> Upstream primer for PCR amplification of mouse TLR9 mRNA
<400> 19
tcgctcaaca agtacacgc

<210> 20
<211> 19
<212> DNA
<213> Downstream primer for PCR amplification of mouse TLR9 mRNA
<400> 20
gctctgcatc atctgcctc

<210> 21
<211> 19
<212> DNA
<213> Upstream primer for PCR amplification of mouse MyD88 mRNA
<400> 21
actcgcagtt tgttggatg

<210> 22
<211> 19
<212> DNA
<213> Downstream primer for PCR amplification of mouse MyD88 mRNA
<400> 22
cacctgtaaa ggcttctcg

<210> 23
<211> 20
<212> DNA
<213> Upstream primer for PCR amplification of mouse GAPDH mRNA
ctgcaccacc aactgcttag

<210> 24
<211> 20
<212> DNA
<213> Downstream primer for PCR amplification of mouse GAPDH mRNA
<400> 24
gtctgggatg gaaattgtga




Claims

1. Use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease caused by bacteria.
 
2. The use of claim 1 wherein said Kukoamine A and Kukoamine B are extracted from Lycii cortex of traditional Chinese medicine.
 
3. The use of claim 2 wherein said Lycii cortex is the dried root bark of Lycium chinense Mill. or Lycium barbarum L of the Solanaceae family.
 
4. The use of claim 1 wherein said drugs are used for antagonizing the key factors which leads to sepsis and autoimmune disease, bacterial endotoxin/lipopolysaccharide (LPS) and unmethylated DNA (CpG DNA) of bacteria.
 
5. Kukoamine A and Kukoamine B for use in the prevention and treatment of sepsis and autoimmune disease caused by bacteria.
 
6. Kukoamine A and Kukoamine B for use of claim 5, wherein said Kukoamine A and Kukoamine B are extracted from Lycii cortex of traditional Chinese medicine.
 
7. Kukoamine A and Kukoamine B for use of claim 6, wherein said Lycii cortex is the dried root bark of Lycium chinense Mill. or Lycium barbarum L of the Solanaceae family.
 
8. Kukoamine A and Kukoamine B for use of claim 5, wherein said Kukoamine A and Kukoamine B are used for antagonizing the key factors which leads to sepsis and autoimmune disease, bacterial endotoxin/lipopolysaccharide (LPS) and unmethylated DNA (CpG DNA) of bacteria.
 


Ansprüche

1. Verwendung von Kukoamin A und Kukoamin B in der Herstellung von Wirkstoffen für die Prävention und Behandlung von durch Bakterien verursachter Sepsis und Autoimmunerkrankung.
 
2. Verwendung nach Anspruch 1, wobei das Kukoamin A und Kukoamin B aus dem Lycii cortex traditioneller chinesischer Medizin extrahiert sind.
 
3. Verwendung nach Anspruch 2, wobei der Lycii cortex die getrocknete Wurzelrinde von Lycium chinense Mill. oder Lycium barbarum L aus der Familie Solanaceae ist.
 
4. Verwendung nach Anspruch 1, wobei die Wirkstoffe zur Antagonisierung der Schlüsselfaktoren verwendet werden, die zu Sepsis und Autoimmunerkrankung führen, bakterielles Endotoxin/Lipopolysaccharid (LPS) und unmethylierte DNA (CpG DNA) von Bakterien.
 
5. Kukoamin A und Kukoamin B zur Verwendung in der Prävention und Behandlung von durch Bakterien verursachter Sepsis und Autoimmunerkrankung.
 
6. Kukoamin A und Kukoamin B zur Verwendung nach Anspruch 5, wobei das Kukoamin A und Kukoamin B aus dem Lycii cortex traditioneller chinesischer Medizin extrahiert sind.
 
7. Kukoamin A und Kukoamin B zur Verwendung nach Anspruch 6, wobei der Lycii cortex die getrocknete Wurzelrinde von Lycium chinense Mill. oder Lycium barbarum L aus der Familie Solanaceae ist.
 
8. Kukoamin A und Kukoamin B zur Verwendung nach Anspruch 5, wobei das Kukoamin A und Kukoamin B zur Antagonisierung der Schlüsselfaktoren verwendet werden, die zu Sepsis und Autoimmunerkrankung führen, bakterielles Endotoxin/Lipopolysaccharid (LPS) und unmethylierte DNA (CpG DNA) von Bakterien.
 


Revendications

1. Utilisation de Kukoamine A et de Kukoamine B dans la préparation de médicaments destinés à la prévention et au traitement d'une septicémie et d'une maladie auto-immune provoquée par des bactéries.
 
2. Utilisation selon la revendication 1, dans laquelle la Kukoamine A et la Kukoamine B sont extraites du cortex de Lycii de la médecine traditionnelle chinoise.
 
3. Utilisation selon la revendication 2, dans laquelle ledit cortex de Lycii est l'écorce de racine séchée de Lycium chinense Mill. ou de Lycium barbarum L de la famille des solanacées.
 
4. Utilisation selon la revendication 1, dans laquelle lesdits médicaments sont utilisés pour antagoniser les facteurs clés qui conduisent à une septicémie et une maladie auto-immune, une endotoxine/lipopolysaccharide (LPS) bactérienne et un ADN non méthylé (ADN CpG) de bactéries.
 
5. Kukoamine A et Kukoamine B destinées à une utilisation dans la prévention et le traitement d'une septicémie et d'une maladie auto-immune provoquée par des bactéries.
 
6. Kukoamine A et Kukoamine B destinées à une utilisation selon la revendication 5, dans lesquelles lesdites Kukoamine A et Kukoamine B sont extraites du cortex de Lycii de la médecine traditionnelle chinoise.
 
7. Kukoamine A et Kukoamine B destinées à une utilisation selon la revendication 6, dans lesquelles ledit cortex de Lycii est l'écorce de racine séchée de Lycium chinense Mill. ou de Lycium barbarum L de la famille des solanacées.
 
8. Kukoamine A et Kukoamine B destinées à une utilisation selon la revendication 5, dans lesquelles lesdites Kukoamine A et Kukoamine B sont utilisées pour antagoniser les facteurs clés qui conduisent à une septicémie et une maladie auto-immune, une endotoxine/lipopolysaccharide (LPS) bactérienne et un ADN non méthylé (ADN CpG) de bactéries.
 




Drawing



















































































Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description